<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomedicines</journal-id><journal-id journal-id-type="iso-abbrev">Biomedicines</journal-id><journal-id journal-id-type="pmc-domain-id">3168</journal-id><journal-id journal-id-type="pmc-domain">biomedicines</journal-id><journal-id journal-id-type="publisher-id">biomedicines</journal-id><journal-title-group><journal-title>Biomedicines</journal-title></journal-title-group><issn pub-type="epub">2227-9059</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11591560</article-id><article-id pub-id-type="pmcid-ver">PMC11591560.1</article-id><article-id pub-id-type="pmcaid">11591560</article-id><article-id pub-id-type="pmcaiid">11591560</article-id><article-id pub-id-type="pmid">39595201</article-id><article-id pub-id-type="doi">10.3390/biomedicines12112637</article-id><article-id pub-id-type="publisher-id">biomedicines-12-02637</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Changes in IL-6, IL-12, IL-5, IL-10 and TGF-&#946;1 Concentration in Patients with Treatment-Resistant Schizophrenia (TRS) Following Electroconvulsive Therapy (ECT)&#8212;A Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9184-342X</contrib-id><name name-style="western"><surname>Szota</surname><given-names initials="AM">Anna Maria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-biomedicines-12-02637" ref-type="aff">1</xref><xref rid="c1-biomedicines-12-02637" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Radajewska</surname><given-names initials="I">Izabela</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-biomedicines-12-02637" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0524-0911</contrib-id><name name-style="western"><surname>&#262;wikli&#324;ska-Jurkowska</surname><given-names initials="M">Ma&#322;gorzata</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-biomedicines-12-02637" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2651-8468</contrib-id><name name-style="western"><surname>Lis</surname><given-names initials="K">Kinga</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af3-biomedicines-12-02637" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0447-142X</contrib-id><name name-style="western"><surname>Grudzka</surname><given-names initials="P">Przemys&#322;aw</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-biomedicines-12-02637" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7880-287X</contrib-id><name name-style="western"><surname>Dr&#243;&#380;d&#380;</surname><given-names initials="W">Wiktor</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-biomedicines-12-02637" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Werner</surname><given-names initials="FM">Felix-Martin</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-biomedicines-12-02637"><label>1</label>Department of Psychiatry, Ludwig Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Curie-Sk&#322;odowskiej Street 9, 85-094 Bydgoszcz, Poland; <email>izabela.radajewska@cm.umk.pl</email> (I.R.); <email>przemyslaw.grudzka@cm.umk.pl</email> (P.G.); <email>wikdr@cm.umk.pl</email> (W.D.)</aff><aff id="af2-biomedicines-12-02637"><label>2</label>Department of Biostatistics and Biomedical Systems Theory, Ludwig Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Jagiellonska Street 13-15, 85-067 Bydgoszcz, Poland; <email>mjurkowska@cm.umk.pl</email></aff><aff id="af3-biomedicines-12-02637"><label>3</label>Department of Alergology, Clinical Immunology and Internal Diseases, Ludwig Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Ujejskiego Street 75, 85-168 Bydgoszcz, Poland; <email>kinga.lis@cm.umk.pl</email></aff><author-notes><corresp id="c1-biomedicines-12-02637"><label>*</label>Correspondence: <email>anna.szota@cm.umk.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2024</year></pub-date><volume>12</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">475809</issue-id><elocation-id>2637</elocation-id><history><date date-type="received"><day>22</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>27</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-27 14:25:17.533"><day>27</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="biomedicines-12-02637.pdf"/><abstract><p><bold>Background/Objectives:</bold> Treatment-resistant schizophrenia (TRS) may be considered as a neuro-immune disorder. Electroconvulsive therapy (ECT) remains an important therapeutic option for patients with TRS, however, its impact on cytokine profile is barely investigated. Therefore, this study attempts to establish associations between serum cytokines IL-6, IL-12, IL-5, IL-10 and TGF-&#946;1 changes (pre- and post-ECT) and the effectiveness of ECT in TRS patients. The second aim is to search for correlations between serum concentrations of the above specified cytokines and psychometric assessments of clinical schizophrenia symptoms. <bold>Methods:</bold> The cytokine concentrations were measured in eight TRS patients on psychopharmacological treatment prior to and following ECT and in 13 control subjects. Psychopathology assessment was based on the Positive and Negative Syndrome Scale (PANSS). <bold>Results</bold>: Prior to ECT, IL-10 concentration was significantly higher in TRS patients, while IL-5 was decreased in comparison to the controls. A significant concentration decrease in the pro-inflammatory cytokines IL-6 (<italic toggle="yes">p</italic> = 0.012), IL-12 (<italic toggle="yes">p</italic> = 0.049) and anti-inflammatory IL-10 (<italic toggle="yes">p</italic> = 0.012) post-ECT vs. pre-ECT was observed, whereas concentrations of IL-5 and TGF-&#946;1 did not significantly change. Also, a significant decrease in schizophrenia symptoms measured by the PANSS post-ECT was found. Furthermore, the pattern of correlations between PANSS scores and cytokine concentrations was different when comparing levels pre- and post-ECT. Additionally, correlations between changes in PANSS scores and cytokine concentrations were found. <bold>Conclusions:</bold> These results may indicate the probable impact of electroconvulsive therapy on the balance between pro- and anti-inflammatory cytokines, which may correspond to a neurobiological therapeutic effect of ECT in TRS patients.</p></abstract><kwd-group><kwd>electroconvulsive therapy (ECT)</kwd><kwd>schizophrenia</kwd><kwd>cytokines</kwd><kwd>interleukins</kwd><kwd>antipsychotic drugs</kwd></kwd-group><funding-group><award-group><funding-source>Nicolaus Copernicus University Reserve</funding-source></award-group><funding-statement>Publication financed from the Nicolaus Copernicus University Reserve for the Basic Research Activity.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-biomedicines-12-02637"><title>1. Introduction</title><p>Schizophrenia (SCZ) is a chronic, debilitating psychotic disorder with heterogenous symptomatology, which includes positive symptoms (hallucinations and delusions), negative symptoms (social withdrawal, apathy, anhedonia and blunted affect) and cognitive dysfunction [<xref rid="B1-biomedicines-12-02637" ref-type="bibr">1</xref>,<xref rid="B2-biomedicines-12-02637" ref-type="bibr">2</xref>]. SCZ phenotypes include first-episode psychosis, acute schizophrenia episodes, chronic and deficit SCZ but also treatment-resistant schizophrenia (TRS) [<xref rid="B3-biomedicines-12-02637" ref-type="bibr">3</xref>,<xref rid="B4-biomedicines-12-02637" ref-type="bibr">4</xref>]. Regardless of the schizophrenia phenotype, incidence is associated with genetic predisposition [<xref rid="B5-biomedicines-12-02637" ref-type="bibr">5</xref>], infection [<xref rid="B6-biomedicines-12-02637" ref-type="bibr">6</xref>], autoimmune conditions [<xref rid="B7-biomedicines-12-02637" ref-type="bibr">7</xref>] but also with activation of the immune system [<xref rid="B2-biomedicines-12-02637" ref-type="bibr">2</xref>,<xref rid="B3-biomedicines-12-02637" ref-type="bibr">3</xref>,<xref rid="B4-biomedicines-12-02637" ref-type="bibr">4</xref>,<xref rid="B8-biomedicines-12-02637" ref-type="bibr">8</xref>].</p><p>Treatment-resistant schizophrenia (TRS) is usually defined as a lack of response to at least two first-line antipsychotic drugs at an adequate dosage, appropriate treatment duration and confirmed compliance [<xref rid="B9-biomedicines-12-02637" ref-type="bibr">9</xref>]. TRS affects 20&#8211;30% of patients with schizophrenia (SZ), resulting in poor daily functioning, reduced quality of life, increased numbers of hospitalization and a higher level of unemployment in comparison to treatment responders [<xref rid="B10-biomedicines-12-02637" ref-type="bibr">10</xref>]. Development of TRS, at least in part, is caused by the deregulation of immune processes reflected by fluctuating levels of inflammatory molecules [<xref rid="B11-biomedicines-12-02637" ref-type="bibr">11</xref>,<xref rid="B12-biomedicines-12-02637" ref-type="bibr">12</xref>].</p><p>Studies conducted so far have revealed that TRS may be considered as a neuro-immune disorder characterized by an activated Inflammatory Response System (IRS), which is counterbalanced by a conversely activated Compensatory Immune Response System (CIRS). IRS activation refers to an increase in the production of pro-inflammatory cytokines by M1 macrophages (IL-1&#946;, IL-6, and tumor necrosis factor-alpha [TNF-&#945;]), Th-1 (IL-2, IL-12, and interferon-gamma [IFN-&#947;]) and Th-17 (IL-17) cells. In contrast, CIRS activation produces more anti-inflammatory factors, involving Th-2 (IL-4, IL-5) and T regulatory (Treg; IL-10 and TGF-&#946;1) immune cells [<xref rid="B4-biomedicines-12-02637" ref-type="bibr">4</xref>,<xref rid="B13-biomedicines-12-02637" ref-type="bibr">13</xref>,<xref rid="B14-biomedicines-12-02637" ref-type="bibr">14</xref>,<xref rid="B15-biomedicines-12-02637" ref-type="bibr">15</xref>]. Increased IRS activation and overproduction of pro-inflammatory cytokines released by M1 and Th-1 have many adverse effects on neuronal cells, including oxidative damage to neurons, changes in neuroplasticity and neuronal signaling, and decreasing neurogenesis, which may be indicators of the neuroprogression of schizophrenia. Released cytokines may cross the blood&#8211;brain barrier (BBB), causing changes in the central inflammatory process (sustaining neuroinflammation) and activating astrocytes and microglia to produce cytokines [<xref rid="B16-biomedicines-12-02637" ref-type="bibr">16</xref>,<xref rid="B17-biomedicines-12-02637" ref-type="bibr">17</xref>]. Activated microglia secreting IL-1&#945;, and TNF may cause neuronal and glial death [<xref rid="B18-biomedicines-12-02637" ref-type="bibr">18</xref>] leading to the progressive loss of brain tissue in schizophrenia [<xref rid="B19-biomedicines-12-02637" ref-type="bibr">19</xref>]. Moreover, activated Th-1 and M1 subsets stimulate the production of neurotoxic tryptophan catabolites (TRYCATs), including picolinic and quinolinic acids, which may cause cognitive impairments in TRS patients [<xref rid="B20-biomedicines-12-02637" ref-type="bibr">20</xref>,<xref rid="B21-biomedicines-12-02637" ref-type="bibr">21</xref>]. Increased production of IRS cytokines also has an impact on the induction of both negative symptoms of schizophrenia and PHEM (psychosis, hostility, excitation and mannerism) symptoms [<xref rid="B3-biomedicines-12-02637" ref-type="bibr">3</xref>].</p><p>Simultaneously, pro-inflammatory cytokines such as IL-6, IL-1&#946; and TNF-&#945; promote liver production of acute-phase proteins, such as C-reactive protein (CRP), Hpx, alpha-1 antitrypsin, Hp, alpha 1S and alpha-2 macroglobulin, which, except for CRP, have significant anti-inflammatory effects. These proteins stimulate the production of anti-inflammatory IL-10 and heme-oxygenase-1 and attenuate production of pro-inflammatory IL-8 and IL-17 [<xref rid="B22-biomedicines-12-02637" ref-type="bibr">22</xref>]. In addition, alpha-2 macroglobulin shows potent anti-inflammatory and antioxidant effects by binding to pro-inflammatory cytokines (IL-6, IL-1&#946; and TNF-&#945;) [<xref rid="B23-biomedicines-12-02637" ref-type="bibr">23</xref>].</p><p>An exaggerated IRS response is counterbalanced by the activation of the CIRS system (anti-inflammatory cytokines production) and neurotrophic defenses (including antioxidants and brain-derived neurotrophic factor (BDNF) production), but this is relatively inadequate to inhibit IRS activation; therefore, impairments in the CIRS response are correlated with the severity of schizophrenia symptoms and poor clinical outcomes in TRS [<xref rid="B4-biomedicines-12-02637" ref-type="bibr">4</xref>,<xref rid="B14-biomedicines-12-02637" ref-type="bibr">14</xref>,<xref rid="B24-biomedicines-12-02637" ref-type="bibr">24</xref>]. Even with remission of schizophrenia symptoms using antipsychotic treatment, both the IRS and CIRS remain overactive, suggesting a new homeostatic set-point between both components [<xref rid="B4-biomedicines-12-02637" ref-type="bibr">4</xref>,<xref rid="B25-biomedicines-12-02637" ref-type="bibr">25</xref>].</p><p>Currently available studies have revealed that TRS is associated with elevated levels of some pro- and anti-inflammatory cytokines, including interleukins such as IL-2, IL-6, IL-12, IL-10, IL-17A, beta2 microglobulin (B2M), IL-6 receptor (IL-6R), IL-1R antagonist (IL-1RA), interferon &#947; (IFN-&#947;), macrophage inflammatory protein 1&#945; (MIP-1&#945;) and chemokines (CCL2, CCL3, CCL11), but the results are inconsistent, so further research in this area is required [<xref rid="B4-biomedicines-12-02637" ref-type="bibr">4</xref>,<xref rid="B8-biomedicines-12-02637" ref-type="bibr">8</xref>,<xref rid="B11-biomedicines-12-02637" ref-type="bibr">11</xref>,<xref rid="B26-biomedicines-12-02637" ref-type="bibr">26</xref>,<xref rid="B27-biomedicines-12-02637" ref-type="bibr">27</xref>].</p><p>The recommended option of treatment for TRS patients is electroconvulsive therapy (ECT) [<xref rid="B28-biomedicines-12-02637" ref-type="bibr">28</xref>,<xref rid="B29-biomedicines-12-02637" ref-type="bibr">29</xref>,<xref rid="B30-biomedicines-12-02637" ref-type="bibr">30</xref>]. A recent meta-analysis has shown the efficacy of ECT in the improvement of global and positive symptoms of schizophrenia (10 studies, effect size = 0.45), but not in negative symptoms, in comparison to continuation of antipsychotic treatment [<xref rid="B31-biomedicines-12-02637" ref-type="bibr">31</xref>]. The neurobiological mechanisms leading to the therapeutic effects of ECT are not yet fully understood, but research has revealed the involvement of the acceleration of neural network activity, neurogenesis promotion, neural hyperconnectivity, normalization of the activity of hormonal axis (i.e., the hypothalamus&#8211;pituitary&#8211;adrenal [HPA]) and the hypothalamus&#8211;pituitary&#8211;thyroid [HPT]) and also a reduction in the neuroinflammatory state [<xref rid="B32-biomedicines-12-02637" ref-type="bibr">32</xref>].</p><p>To the best of our knowledge, there are just a few studies that focus on the impact of ECT on the immune system in TRS patients. The research conducted so far in TRS patients looks at molecules such as brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), TNF-&#945;, IL-4, transforming growth factor &#946;1 (TGF-&#946;1), myeloperoxidase (MPO) and nuclear factor-kB (NF-kB). It has been found that ECT may have a twofold influence on the concentration of BNDF and VEGF. Some studies have documented a significant increase in BDNF and VEGF serum levels associated with the therapeutic action of ECT [<xref rid="B33-biomedicines-12-02637" ref-type="bibr">33</xref>,<xref rid="B34-biomedicines-12-02637" ref-type="bibr">34</xref>,<xref rid="B35-biomedicines-12-02637" ref-type="bibr">35</xref>,<xref rid="B36-biomedicines-12-02637" ref-type="bibr">36</xref>], whereas other studies have reported no changes in BDNF and VEGF post ECT vs. pre-ECT [<xref rid="B37-biomedicines-12-02637" ref-type="bibr">37</xref>,<xref rid="B38-biomedicines-12-02637" ref-type="bibr">38</xref>,<xref rid="B39-biomedicines-12-02637" ref-type="bibr">39</xref>,<xref rid="B40-biomedicines-12-02637" ref-type="bibr">40</xref>]. Kartalci et al., 2016 [<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>] reported a significant increase in serum concentrations of IL-4 and TGF-&#946;1 post-ECT in comparison to pre-ECT, and also a correlation between this effect and a clinical improvement (decrease of schizophrenia symptoms) in TRS patients. Also, MPO and NF-kB concentrations were unaffected by ECT [<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>]. In the case of TNF-&#945;, a decrease post-ECT v. pre-ECT was noticed [<xref rid="B40-biomedicines-12-02637" ref-type="bibr">40</xref>]. Additionally, regarding BDNF, VEGF and TNF-&#945;, there were no significant concentration differences between TRS patients and control subjects [<xref rid="B40-biomedicines-12-02637" ref-type="bibr">40</xref>].</p><p>Bearing in mind that TRS may be considered a neuro-immune disorder and is based on the scarce, aforementioned research on the involvement of particular cytokines in TRS development and their changes following ECT, our pioneering study is justified.</p><p>Therefore, this study attempts to establish associations between serum cytokines IL-6, IL-12, IL-5, IL-10 and TGF-&#946;1 changes and the effectiveness of ECT in treatment-resistant schizophrenia patients. The second aim is to search for correlations between serum concentrations of the above specified cytokines and psychometric assessments of clinical schizophrenia symptoms performed with the Positive and Negative Syndrome Scale (PANSS).</p></sec><sec id="sec2-biomedicines-12-02637"><title>2. Materials and Methods</title><sec id="sec2dot1-biomedicines-12-02637"><title>2.1. Patients, Inclusion and Exclusion Criteria</title><p>This study was conducted at the Psychiatry Clinic of the University Hospital no 1 in Bydgoszcz (Poland). Participants were inpatients with treatment-resistant schizophrenia referred for ECT by their psychiatrist. The recruitment period lasted from December 2018 to February 2020 but was untimely finished because of the COVID-19 pandemic. These patients typically failed to achieve a clinical response to at least three separate trials of antipsychotic medication at a sufficient dose. The number of ECT sessions to be administered was based on the patient&#8217;s clinical response. A total of 8 patients (5 men and 3 women, mean age 35) were recruited. A detailed description of included patients is given in <xref rid="biomedicines-12-02637-t001" ref-type="table">Table 1</xref>.</p><p>The study inclusion criteria comprised patients aged 18&#8211;65 years diagnosed with schizophrenia (paranoid or residual) according to the ICD-10, who fulfilled the criteria of drug resistance. Exclusion criteria from the study were serious neurological diseases, current addiction to alcohol or psychoactive substances, autoimmune diseases, lack of informed consent to electroconvulsive therapy and contraindications to conduct ECT such as myocardial infarction within the last 3 months, decompensated heart failure, severe valvular heart defects, unstable angina, complex arrhythmias, aortic aneurysm, uncontrolled diabetes mellitus, decompensated renal failure, severe metabolic disorders, severe lung disease, acute glaucoma attack, stroke within the last 4 weeks, intracranial neoplasm and retinal detachment.</p><p>A total of 13 healthy subjects (2 men and 11 women, mean age 33 years) with no history of past or current mental disorders were recruited as a control group. After the procedures were fully explained, written informed consent was obtained from all subjects to participate in the study. The current study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nicolaus Copernicus University in Toru&#324; Collegium Medicum in Bydgoszcz, Poland. Approval number KB 631/2018, obtained on 24 October 2018.</p><p>The male/female ratio was 5/3. Patients were aged 20&#8211;41 years, with the mean being 35 years. The length of disease in the group was between 3 and 23 years, with the mean being 13.9 years and median being 16 years. Two patients were diagnosed with residual schizophrenia and six with paranoid type according to the ICD-10 criteria. Only one individual had been previously treated with ECT. Three patients had history of suicidal attempt/s. Five subjects were diagnosed with past or current SUD; however, two of them had nicotinism only. All patients were treated with at least two antipsychotics and satisfied criteria of treatment-resistant schizophrenia [<xref rid="B9-biomedicines-12-02637" ref-type="bibr">9</xref>,<xref rid="B42-biomedicines-12-02637" ref-type="bibr">42</xref>]. Moreover, five subjects met criteria for ultra-treatment-resistant schizophrenia [<xref rid="B9-biomedicines-12-02637" ref-type="bibr">9</xref>,<xref rid="B43-biomedicines-12-02637" ref-type="bibr">43</xref>] and all of them were treated with higher chlorpromazine equivalent antipsychotic dosage as compared to those not treated with clozapine. Four patients took a remarkably high combined antipsychotic dose expressed in chlorpromazine equivalent (&gt;1000 mg a day). The mean antipsychotics&#8217; dose calculated as chlorpromazine equivalent for the group was 1108 mg a day and median 913 mg a day [<xref rid="B44-biomedicines-12-02637" ref-type="bibr">44</xref>]. This suggests the severity of disease. The mean post-ECT PANSS score improvement in the group on all subscales and in total was at least 30% and may be regarded satisfactory against treatment-resistance. These 3 individuals were continuing the phramacological treatment, so it should be suitable for treatment. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://psychopharmacopeia.com/antipsychotic_conversion.php">https://psychopharmacopeia.com/antipsychotic_conversion.php</uri>; accessed on 10 June 2024. Antipsychotic Dose Conversion Calculator.</p></sec><sec sec-type="methods" id="sec2dot2-biomedicines-12-02637"><title>2.2. ECT Treatment Procedures</title><p>Before undergoing ECT, each patient was screened for general health through a physical and neurological examination, blood and urine tests, electrocardiogram and a cerebral computed tomography scan. The severity of schizophrenia symptoms was evaluated twice by conducting the PANSS, before ECT and after the last session of ECT. Each patient underwent 3 sessions of ECT per week for a mean number of 13 ECT sessions (range: 11&#8211;15). Only one patient had a history of ECT. A brief-pulse machine generating bipolar square waves was used (Thymatron System IV, Somatics; Lake Bluff, IL, USA). Electrodes were positioned bilaterally on the frontal&#8211;temporal region. Only one adequate seizure was required for each session, which was defined as an electroencephalographic seizure lasting more than 20 s with a high-amplitude, slow wave and postictal suppression. The electrical dose was maintained at the threshold level unless short seizures occurred, in which case the charge was increased by 50%. Anesthesia was induced with i.v. thiopental (3&#8211;4 mg/kg, i.v.) and succinylcholine (0.5&#8211;1.5 mg/kg, i.v.). The total number of ECT sessions for each patient was determined by the consensus opinion of the medical staff based on clinical improvement and adverse effects.</p></sec><sec id="sec2dot3-biomedicines-12-02637"><title>2.3. Interleukins Assay</title><p>For cytokine analysis, venous blood samples were collected from all of the patients with schizophrenia between 7.00 and 7.30 a.m. pre-ECT and after the last ECT session. The blood samples were drawn into anticoagulant free tubes and after 45 min, serum was separated by centrifugation at 3000 rpm for 10 min at 4 &#176;C. Then, the serum samples were pipetted into sterile 1.5 mL microcentrifuge tubes and stored at &#8722;80 &#176;C until assay. Also, the venous blood was collected once on a screening day from healthy people who comprised the control group. All samples were analyzed using ELISA kits (Diaclone, Medics Biochemica Group, Besan&#231;on, France) according to the manufacturer&#8217;s protocol. Cytokine levels are expressed as pg/mL.</p></sec><sec id="sec2dot4-biomedicines-12-02637"><title>2.4. Statistical Methods</title><p>To support the limited number of patients, special statistical analysis was performed. To improve the power of the tests, the values were logarithmized to obtain normal distributions. Additionally, to avoid the drawbacks of the relatively small samples and to increase the power, Bayesian analyses were applied. Bayesian related-sample inference was employed for comparison of the cytokines before and after ECT. For the testing of any differences between distributions of results pre- and post-ECT, a Bayesian Student <italic toggle="yes">t</italic>-test was applied. Similarly, Bayesian related-sample inference was applied for comparison of the PANSS scores before and after ECT. Additionally, Bayesian independent sample inference was applied for testing the hypotheses concerning the comparison of cytokine concentrations in patients before ECT with controls. Also, Bayesian independent sample inference was applied for testing the hypotheses concerning comparison of cytokine concentrations in patients following ECT with controls. For the testing of differences between distributions of results pre-ECT with the control group or post-ECT with the control group, Bayesian <italic toggle="yes">t</italic>-tests for independent variables were applied. Correlations were calculated with Spearman statistics and a scatterplot for two-dimensional distributions is presented with fitted lines and determination coefficients. PS IMAGO PRO v. 9.0 package was used for calculations <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://en.predictivesolutions.pl/en/ps-imago-pro">https://en.predictivesolutions.pl/en/ps-imago-pro</uri>; Accessed on 10 October 2024. </p></sec></sec><sec sec-type="results" id="sec3-biomedicines-12-02637"><title>3. Results</title><sec id="sec3dot1-biomedicines-12-02637"><title>3.1. Changes in Cytokine Concentration and PANSS Score Following ECT</title><p>After logarithmization, normal distributions for both cytokines and PANSS scores were obtained, according to Shapiro&#8211;Wilk tests on the 0.05 levels. Thus, Bayesian inference for normal distributions was applied [<xref rid="B45-biomedicines-12-02637" ref-type="bibr">45</xref>,<xref rid="B46-biomedicines-12-02637" ref-type="bibr">46</xref>,<xref rid="B47-biomedicines-12-02637" ref-type="bibr">47</xref>]. A significant decrease in the PANSS positive symptoms, PANSS negative symptoms, PANSS general symptoms and PANSS total score in schizophrenic patients was observed (<xref rid="biomedicines-12-02637-t002" ref-type="table">Table 2</xref>). This reflects substantial improvement in psychopathology following ECT.</p><p>The results of cytokine concentrations are presented in <xref rid="biomedicines-12-02637-t003" ref-type="table">Table 3</xref> with means and standard deviations (SDs). According to the <italic toggle="yes">p</italic>-values of the Shapiro&#8211;Wilk test after logarithmization, both pre-ECT and post-ECT results were compared, and Bayesian <italic toggle="yes">t</italic>-tests for dependent variables were employed. Similarly, for comparisons to the control group, the Shapiro&#8211;Wilk test did not reject the hypothesis of normality in both compared groups. According to the <italic toggle="yes">p</italic>-value calculated on this, a Bayesian <italic toggle="yes">t</italic>-test for unpaired samples was employed.</p><p>We observed significant changes post-ECT vs. pre-ECT for pro-inflammatory cytokines: IL-6, IL-12 and anti-inflammatory IL-10 and all medians decreased (<xref rid="biomedicines-12-02637-t003" ref-type="table">Table 3</xref>). When comparing pre-ECT cytokine concentrations with the control group, significant differences were found for IL-10. When comparing post-ECT cytokine concentrations with the control group, significant differences were observed for IL-6.</p></sec><sec id="sec3dot2-biomedicines-12-02637"><title>3.2. Correlations Between Cytokines and PANSS Scores During ECT</title><p>Correlations r are given in the table with marked significant values, according to the calculated probability of &gt;|r| under the assumption of the null hypothesis of zero correlation.</p><p>The Spearman correlations were calculated for cytokines and the PANSS scores before ECT (lower triangle in <xref rid="biomedicines-12-02637-t004" ref-type="table">Table 4</xref>) and following ECT (upper triangle in <xref rid="biomedicines-12-02637-t004" ref-type="table">Table 4</xref>). There were significant positive correlations between the scores of the PANSS subscales and the PANSS total scores before ECT, but only one significant correlation 0.882 following ECT.</p><p>All corresponding PANSS subscales or total scale before and following ECT were highly positively correlated (diagonal values in <xref rid="biomedicines-12-02637-t004" ref-type="table">Table 4</xref>). Moreover, we found a highly significant negative correlation between TGF-&#946;1 and the PANSS positive symptoms following ECT (r = &#8722;0.790, <italic toggle="yes">p</italic> = 0.02). This means that a higher intensity of positive symptoms on the PANSS at ECT completion was related to smaller TGF-&#946;1 values in TRS patients.</p><p>The only significant positive correlation between cytokine concentrations in the control group was found for TGF-&#946;1 and IL-6 (<xref rid="biomedicines-12-02637-t005" ref-type="table">Table 5</xref>).</p><p>Correlations between cytokine concentration changes, changes on the PANSS subscales and total score following ECT (columns) with variables referring to both cytokine concentrations and psychometric assessments (rows) were calculated for patients and the results are presented in <xref rid="biomedicines-12-02637-t006" ref-type="table">Table 6</xref> and <xref rid="biomedicines-12-02637-t007" ref-type="table">Table 7</xref>. Significant correlations have been marked.</p><p>A higher concentration of pre-ECT IL-12 correlated positively (0.93) with a significant decrease in IL-12 post-ECT. Greater intensity of positive symptoms on the PANSS before ECT was positively associated (r = 0.71) with a significant decrease in the score on the PANSS positive subscale as a result of ECT. Higher scores on the PANSS negative symptoms subscales before ECT were positively correlated with a greater decrease in the total PANSS score following ECT (0.84). Both general symptom intensity and total score of the pre-ECT PANSS were associated positively with a more pronounced decrease in the PANSS total score post-ECT (0.85 and 0.85).</p><p>A higher IL-12 concentration following ECT was positively correlated with a greater decrease in both negative symptoms score and total score of the PANNS (r = 0.87 and 0.74, respectively). A lower post-ECT IL-5 concentration was associated with a greater decrease in IL-5 as a consequence of ECT (&#8722;0.98). Similarly, lower concentration of TGF-&#946;1 following ECT correlated with both IL-6 and TGF-&#946;1 decreased due to ECT (r = &#8722;0.76 and &#8722;0.93, respectively; <xref rid="biomedicines-12-02637-t006" ref-type="table">Table 6</xref>).</p><p>The results of correlations between changes in cytokine concentrations and changes in the PANSS scores pre- to post-ECT indicate that the decrease in total PANSS score was positively correlated with a decreased intensity of negative and general symptoms (r = 0.77 and 0.81). Thus, patients with a higher decrease in total PANSS score also had a higher decrease in negative and general symptoms. The only significant correlation among cytokines was a positive association between changes in IL-6 and TGF-&#946;1 concentrations pre- to post-ECT (0.83, <xref rid="biomedicines-12-02637-t007" ref-type="table">Table 7</xref>). Thus, patients with a higher decrease or increase in IL-6 concentrations also had a higher decrease or increase (respectively) in concentrations of TGF-&#946;1. Interestingly, the same correlation was observed in the control group, i.e., a positive association of IL-6 and TGF-&#946;1 concentrations (0.78, <xref rid="biomedicines-12-02637-t005" ref-type="table">Table 5</xref>).</p><p><xref rid="biomedicines-12-02637-f001" ref-type="fig">Figure 1</xref> presents changes in IL-6 and TGF-&#946;1 concentrations following ECT for each patient. Post-ECT values (triangles) are lower than pre-ECT (circles); however, there is no linear association between these parameters. Conversely, an association between IL-6 and TGF-&#946;1 concentrations in the control group is linear; a corresponding scatterplot for <italic toggle="yes">n</italic> = 13 control subjects on <xref rid="biomedicines-12-02637-f002" ref-type="fig">Figure 2</xref> shows the determination coefficient R<sup>2</sup> = 0.60 and a higher Spearman correlation (r = 0.78; <italic toggle="yes">p</italic> = 0.002) than in schizophrenic patients (both pre- and post-ECT) (compare <xref rid="biomedicines-12-02637-f001" ref-type="fig">Figure 1</xref>).</p><p><xref rid="biomedicines-12-02637-f003" ref-type="fig">Figure 3</xref> shows a scatterplot of the differences of post-ECT from pre-ECT values in IL-6 and TGF-&#946;1, after subtracting coordinates in the horizontal and vertical axes of red and blue points in <xref rid="biomedicines-12-02637-f001" ref-type="fig">Figure 1</xref>. TGF-&#946;1 and IL-6 decreases are significantly dependent with the Spearman correlation at 0.83 (<italic toggle="yes">p</italic> = 0.01). The overlaid parabolic fit line depicts a nonlinear dependence with determination coefficient R<sup>2</sup> = 0.789.</p><p>In summary, the statistical analysis revealed the following: (a) a significant concentration decrease in pro-inflammatory cytokines IL-6 (<italic toggle="yes">p</italic> = 0.012), IL-12 (<italic toggle="yes">p</italic> = 0.049) and anti-inflammatory IL-10 (<italic toggle="yes">p</italic> = 0.012) post-ECT vs. pre-ECT; (b) no significant change in IL-5 and TGF-&#946;1 concentration post-ECT vs. pre-ECT; (c) a significant decrease (<italic toggle="yes">p</italic> &lt; 0.001) in schizophrenia symptoms (a significant decrease in all subscales: positive, negative, general PANSS) and total PANSS score led by ECT; (d) a negative correlation between TGF-&#946;1 and PANSS positive symptoms (r = &#8722;0.790, <italic toggle="yes">p</italic> = 0.05) post-ECT.</p></sec></sec><sec sec-type="discussion" id="sec4-biomedicines-12-02637"><title>4. Discussion</title><p>The main objective of this study was to assess the effects of ECT on cytokines such as IL-6, IL-12, IL-5, IL-10 and TGF-&#946;1 in patients with treatment-resistant schizophrenia. The second aim was to determine correlations between serum levels of the above cytokines and changes in clinical schizophrenia symptoms measured by the Positive and Negative Syndrome Scale (PANSS).</p><p>To the best of our knowledge, the impact of ECT on the concentration of IL-6, IL-12, IL-5 and IL-10 in TRS patients has not yet been the subject of any research conducted so far. Changes in other cytokines, interleukins and neurotrophins post-ECT vs. pre-ECT in TRS patients are summarized in <xref rid="biomedicines-12-02637-t008" ref-type="table">Table 8</xref> together with the results of this study.</p><p>Our study shows that there were no statistically significant differences in blood concentrations of IL-6, IL-12 and TGF-&#946;1 between TRS patients prior to ECT and the control group. However, a decreased concentration of IL-5 and an increased concentration of IL-10 (<italic toggle="yes">p</italic> &lt; 0.001) in TRS patients in comparison to the control group was observed. Our findings on IL-6, IL-12 and TGF-&#946;1 are in opposition to previous results, published by other authors, where increased (IL-6 and IL-12) [<xref rid="B8-biomedicines-12-02637" ref-type="bibr">8</xref>,<xref rid="B25-biomedicines-12-02637" ref-type="bibr">25</xref>,<xref rid="B48-biomedicines-12-02637" ref-type="bibr">48</xref>] or decreased concentrations of IL-12 and TGF-&#946;1 [<xref rid="B25-biomedicines-12-02637" ref-type="bibr">25</xref>,<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>] in TRS patients in comparison to the control group were detected. Also, with regard to the concentration of IL-5 and IL-10 in TRS patients, the results are conflicting. Leboyer et al., 2021 [<xref rid="B8-biomedicines-12-02637" ref-type="bibr">8</xref>], showed no significant differences in IL-5 and an increased concentration of IL-10 in TRS patients as compared to the control group, whereas Chen et al., 2023 [<xref rid="B25-biomedicines-12-02637" ref-type="bibr">25</xref>], showed a decreased concentration of IL-10 in TRS patients. An explanation for such inconsistent results seems to be difficult due to limited evidence resulting from small sample sizes and the heterogeneous population of TRS patients, and the still not adequately understood inflammatory mechanisms underlying drug-resistance in patients with schizophrenia.</p><p>It has been suggested that both IL-6 and TGF-&#946;1 are indicators of acute exacerbations of schizophrenia [<xref rid="B49-biomedicines-12-02637" ref-type="bibr">49</xref>], so their levels are potentially increased during acute states in comparison to the control group [<xref rid="B4-biomedicines-12-02637" ref-type="bibr">4</xref>]. We may only hypothesize that a lack of significant difference in IL-6 and TGF-&#946;1 in TRS patients prior to ECT, in comparison to the control group, may result from a stable mental state in chronic schizophrenia, and not with acute exacerbation of the illness. Also, increased concentration of IL-10 (<italic toggle="yes">p</italic> &lt; 0.001) in our TRS patients may inhibit production of both IL-6 and IL-12, which means their concentrations were not different from the control group. On the other hand, some proteins such as alpha-1 antitrypsin, Hp, alpha 1S and alpha-2 macroglobulin produced by the liver may stimulate the production of IL-10 [<xref rid="B22-biomedicines-12-02637" ref-type="bibr">22</xref>], which exerts an anti-inflammatory effect, as was observed in our TRS patients. In addition, its binding to IL-6 alpha-2 macroglobulin [<xref rid="B23-biomedicines-12-02637" ref-type="bibr">23</xref>] may be a reason why the IL-6 level is not increased in TRS patients. Moreover, our patients were on various combinations of antipsychotic drugs including haloperidol, olanzapine, quetiapine, aripiprazole, clozapine and mood stabilizers; therefore, their possible effect on the immune system has to be taken into account. In vivo research showed that typical antipsychotics suppress plasma IL-6 and IL6R [<xref rid="B13-biomedicines-12-02637" ref-type="bibr">13</xref>], whereas repeated administration of atypical antipsychotics, i.e., clozapine or risperidone, may have a dual effect. Significantly increased plasma concentrations of IL-2R, IL-6 and TNF-&#945; in TRS patients treated with risperidone were found by Maes et al., 1997 [<xref rid="B13-biomedicines-12-02637" ref-type="bibr">13</xref>], Maes et al., 1994 [<xref rid="B50-biomedicines-12-02637" ref-type="bibr">50</xref>], and Tourjman et al., 2013 [<xref rid="B51-biomedicines-12-02637" ref-type="bibr">51</xref>]. Meanwhile, Patlola et al., 2023 [<xref rid="B52-biomedicines-12-02637" ref-type="bibr">52</xref>], in a meta-analysis observed decreased levels of IL-6 and TNF-&#945; after treatment with risperidone vs. before treatment in patients with chronic schizophrenia. With regard to clozapine treatment, there were no significant differences in the concentration of IL-6 and TNF-&#945; after treatment vs. before treatment in patients with chronic schizophrenia [<xref rid="B52-biomedicines-12-02637" ref-type="bibr">52</xref>]. Also, aripiprazole may decrease IL-12 levels in patients with chronic schizophrenia, or may increase IL-10 (<italic toggle="yes">p</italic> &lt; 0.001) levels when used over the long term [<xref rid="B53-biomedicines-12-02637" ref-type="bibr">53</xref>]. Increased IL-10 levels have also been reported in patients with chronic schizophrenia treated with risperidone or clozapine for at least 6 weeks [<xref rid="B54-biomedicines-12-02637" ref-type="bibr">54</xref>]. Therefore, various combinations of antipsychotics may be involved in the lack of differences in IL-6 and IL-12 concentrations as well as in the higher IL-10 concentration in TRS patients pre-ECT in comparison to the controls. Moreover, no differences in the concentration of IL-6 and IL-12 in TRS patients prior to ECT vs. the control group may suggest that IL-6 is a state marker, and simultaneously undermines IL-12 status as a trait marker. Therefore, IL-6 concentration reflects the intensity of symptoms in TRS patients with a tendency for normalization under antipsychotic treatment. A significant increase in IL-6 concentration was found in multiple-episode schizophrenia (MES) patients [<xref rid="B55-biomedicines-12-02637" ref-type="bibr">55</xref>,<xref rid="B56-biomedicines-12-02637" ref-type="bibr">56</xref>]. Antipsychotic treatment in our TRS patients probably decreased IL-6 concentration to similar values as in the control subjects. On the other hand, IL-12 elevation as a trait marker represents the properties of the behavioral and biological processes that play an antecedent, possibly causal, role in the pathophysiology of schizophrenia [<xref rid="B56-biomedicines-12-02637" ref-type="bibr">56</xref>] and is present in acutely relapsed patients and after antipsychotic treatment [<xref rid="B55-biomedicines-12-02637" ref-type="bibr">55</xref>]. Consistently, IL-12 should be higher in our patients on antipsychotic treatment as compared to the control group. However, we did not observe such an effect in our study, so this suggests that IL-12 may not be a trait marker for TRS. More pronounced cytokine alterations have been found to predict a lack of response to antipsychotic treatment and also unfavorable long-term outcomes in schizophrenia [<xref rid="B57-biomedicines-12-02637" ref-type="bibr">57</xref>].</p><p>The latest reviews and meta-analyses have ascertained the impact of various combinations of antipsychotic medications on interleukin concentrations in patients with chronic schizophrenia, but not TRS, and they have given unequivocal results [<xref rid="B52-biomedicines-12-02637" ref-type="bibr">52</xref>,<xref rid="B58-biomedicines-12-02637" ref-type="bibr">58</xref>,<xref rid="B59-biomedicines-12-02637" ref-type="bibr">59</xref>]. There are no data on the impact of combinations of antipsychotics in TRS patients on other cytokines, e.g., IL-2, IL-4, IL-5, IL-10, IL-12, IL-17, IL-23 and TGF-&#946;1, although their involvement in schizophrenia pathophysiology has been demonstrated [<xref rid="B58-biomedicines-12-02637" ref-type="bibr">58</xref>,<xref rid="B60-biomedicines-12-02637" ref-type="bibr">60</xref>]. With this in mind, the results of our study may be perceived as pioneering.</p><p>In our study, correlations between serum levels of cytokines and the PANSS scores pre- and post-ECT were evaluated in TRS patients. No correlation was found between any of the measured cytokines (IL-6, IL-12, IL-5, IL-10, TGF-&#946;1) and positive, negative, general or total PANSS scores pre-ECT. The only available data that our results can be compared with were published by Dahan et al., 2018 [<xref rid="B61-biomedicines-12-02637" ref-type="bibr">61</xref>]. They found a positive, statistically significant correlation between symptom severity measured by the PANSS and IL-6 (r = 0.482, <italic toggle="yes">p</italic> = 0.0039 with the overall score; r = 0.466, <italic toggle="yes">p</italic> = 0.0055, with the general score; r = 0.350, <italic toggle="yes">p</italic> = 0.0425, with the negative scale) [<xref rid="B61-biomedicines-12-02637" ref-type="bibr">61</xref>]. Furthermore, Noto et al., 2015 [<xref rid="B11-biomedicines-12-02637" ref-type="bibr">11</xref>], found correlations between the PANSS negative score and IL-2 (<italic toggle="yes">p</italic> = 0.021, negative association) and CCL11 (<italic toggle="yes">p</italic> = 0.005, positive association) in TRS patients.</p><p>Many more correlations between inflammatory markers and the different types of symptoms in schizophrenia were found in first-episode and drug-na&#239;ve schizophrenia (FEDN), and in patients with chronic schizophrenia. It was found that higher levels of IL-6, IL-1&#946;, IL-33 and IL-17 are associated with more severe positive symptoms [<xref rid="B17-biomedicines-12-02637" ref-type="bibr">17</xref>,<xref rid="B58-biomedicines-12-02637" ref-type="bibr">58</xref>,<xref rid="B62-biomedicines-12-02637" ref-type="bibr">62</xref>,<xref rid="B63-biomedicines-12-02637" ref-type="bibr">63</xref>]. Exacerbated negative symptoms are positively correlated with increased levels of IL-6, IL-1&#946;, IL-4, IL-8, TNF-&#946;, TGF-&#946;1 and IL-13 [<xref rid="B17-biomedicines-12-02637" ref-type="bibr">17</xref>,<xref rid="B57-biomedicines-12-02637" ref-type="bibr">57</xref>,<xref rid="B64-biomedicines-12-02637" ref-type="bibr">64</xref>]; however, the correlation between IL-1&#946; and TNF-&#945; and negative symptoms is only seen in chronic patients [<xref rid="B58-biomedicines-12-02637" ref-type="bibr">58</xref>]. A negative correlation with negative symptoms was found for IL-2 and IL-10 [<xref rid="B58-biomedicines-12-02637" ref-type="bibr">58</xref>]. Also, increased levels of IL-6, IL-33 and TGF-&#946;1 are positively correlated with the general psychopathology sub-score [<xref rid="B54-biomedicines-12-02637" ref-type="bibr">54</xref>,<xref rid="B58-biomedicines-12-02637" ref-type="bibr">58</xref>]. The total PANSS score is positively correlated with the levels of IL-6, IL1&#946;, IFN-&#947;, IL-17 and TGF-&#946;1 [<xref rid="B61-biomedicines-12-02637" ref-type="bibr">61</xref>,<xref rid="B65-biomedicines-12-02637" ref-type="bibr">65</xref>,<xref rid="B66-biomedicines-12-02637" ref-type="bibr">66</xref>].</p><p>It was suggested that on the basis of the correlation between cytokine concentrations and PANSS scores before treatment, it is possible to predict a therapeutic effect of the treatment in some distant future (e.g., at 6-month follow-up). A good example is results obtained by He et al., 2020 [<xref rid="B2-biomedicines-12-02637" ref-type="bibr">2</xref>], in patients with a first episode or relapse of schizophrenia. They found that a higher IL-6 level (<italic toggle="yes">p</italic> = 0.027) and lower IL-8 level (<italic toggle="yes">p</italic> = 0.035) predicted a better therapeutic effect of antipsychotic treatment on negative symptoms. A higher IL-6 concentration also predicted less improvement in depressive symptoms of schizophrenia [<xref rid="B2-biomedicines-12-02637" ref-type="bibr">2</xref>]. As in our results, there was no correlation between any of the measured cytokines (IL-6, IL-12, IL-5, IL-10, TGF-&#946;1) and positive, negative, general or total PANSS scores pre-ECT. A recently published study performed in male schizophrenic patients has revealed that catalase and IL-6 serum elevation could be predictors of treatment-resistance [<xref rid="B67-biomedicines-12-02637" ref-type="bibr">67</xref>]. Other studies in this field were conducted in non-TRS samples [<xref rid="B58-biomedicines-12-02637" ref-type="bibr">58</xref>,<xref rid="B68-biomedicines-12-02637" ref-type="bibr">68</xref>,<xref rid="B69-biomedicines-12-02637" ref-type="bibr">69</xref>,<xref rid="B70-biomedicines-12-02637" ref-type="bibr">70</xref>]. Thus, predictions of a therapeutic effect in TRS using cytokine profiles require further research [<xref rid="B68-biomedicines-12-02637" ref-type="bibr">68</xref>].</p><p>The results of our study revealed a significant decrease in plasma concentrations of IL-6 (<italic toggle="yes">p</italic> = 0.012), IL-12 (<italic toggle="yes">p</italic> = 0.049) and IL-10 (<italic toggle="yes">p</italic> = 0.012) in schizophrenic patients after ECT in comparison to pre-ECT. Also, a significant decrease in the concentration of IL-6 (<italic toggle="yes">p</italic> = 0.005) and IL-12 (<italic toggle="yes">p</italic> = 0.013) after ECT in comparison to the control group was found. With regard to IL-5 and TGF-&#946;1, the change after ECT in comparison to pre-ECT was not significant. To date, studies examining the effect of ECT on the same inflammatory mediators we considered in TRS patients are not available, except Kartalci et al., 2016 [<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>], who showed an increased concentration of TGF-&#946;1(<italic toggle="yes">p</italic> = 0.001) following ECT. Our results seem to be partly in line with those obtained by Kartalci et al., 2016 [<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>], as the concentration of TGF-&#946;1 was increased following ECT, although without reaching statistical significance.</p><p>TGF-&#946;1 modulates anti-inflammatory and repairing processes [<xref rid="B71-biomedicines-12-02637" ref-type="bibr">71</xref>]; thus, its elevation subsequent to ECT seems reasonable. The positive correlation between IL-6 and TGF-&#946;1 observed in our study is in accordance with the findings of Zhang et al., 2005 [<xref rid="B71-biomedicines-12-02637" ref-type="bibr">71</xref>], which may point to a dynamic interplay of both cytokines and their influence on inflammation and healing processes through regulatory T cells (Treg) [<xref rid="B71-biomedicines-12-02637" ref-type="bibr">71</xref>]. This may suggest the ECT stimulation of both pro- and anti-inflammatory systems in the brain that may promote the shaping of a new type of balance between them [<xref rid="B64-biomedicines-12-02637" ref-type="bibr">64</xref>].</p><p>In the case of interleukins such as IL-6, IL-12, IL-5, IL-10 and PANSSs (in all subscales and total PANSS), no correlation was found following ECT. The only significant negative correlation that was noticed was between TGF-&#946;1 and PANSS positive symptoms (r = &#8722;0.790, <italic toggle="yes">p</italic> = 0.05) after ECT. This may indicate that the TGF-&#946;1 concentration increase induced by ECT could be coupled with the attenuation of positive symptoms measured by PANSSs. Interestingly, Kartalci et al., 2016 [<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>], found that TGF-&#946;1 elevation was negatively correlated with the changes in Brief Psychiatric Rating Scale (BPRS) scores following ECT (<italic toggle="yes">p</italic> = 0.04). This may suggest a connection of TGF-&#946;1 anti-inflammatory and repairing properties to the effect of ECT on psychopathology in treatment-resistant schizophrenia.</p><p>Not surprisingly, we observed significant improvements on the PANSS positive, negative, general and also total scores following ECT. The differences in medians were &#8722;9.5; &#8722;11.5; &#8722;18; and &#8722;41, respectively. Previously published studies in TRS patients in which various combinations of antipsychotics, including clozapine, along with ECT were used also noticed such an effect [<xref rid="B64-biomedicines-12-02637" ref-type="bibr">64</xref>,<xref rid="B72-biomedicines-12-02637" ref-type="bibr">72</xref>,<xref rid="B73-biomedicines-12-02637" ref-type="bibr">73</xref>,<xref rid="B74-biomedicines-12-02637" ref-type="bibr">74</xref>,<xref rid="B75-biomedicines-12-02637" ref-type="bibr">75</xref>,<xref rid="B76-biomedicines-12-02637" ref-type="bibr">76</xref>]. The PANSS score reductions observed in these studies were 40&#8211;71% (on all subscales and overall score) and a 40% decrease on the BPRS score, regardless of medication(s) dose(s), years of treatment and number of ECT sessions. Moreover, s meta-analysis including 23 studies found the superior efficacy of ECT augmentation of clozapine (nine studies) compared to ECT augmentation of non-clozapine (typical and atypical) antipsychotics [<xref rid="B77-biomedicines-12-02637" ref-type="bibr">77</xref>]. The majority of the patients enrolled in our study (five out of eight) were on clozapine and therefore a significant decrease in the PANSS scores as a result of ECT could be regarded as both expected and consistent with evidence.</p><p>There is a paucity of high-quality data on brain ECT changes in schizophrenia since the majority of studies are based on small sample sizes of patients continuously treated with antipsychotics and, additionally, they have an observational design. However, the existing evidence indicates a multi-directional and simultaneous influence of this procedure on multiple systems. Among the most important modifications identified are those pertaining to brain morphology and activity as well as hormonal and immune system function. ECT produces intraneuronal (epigenetic) and synaptic remodeling that results in complex and inter-correlated biochemical, structural, neurophysiological, hormonal and immunological transformations [<xref rid="B78-biomedicines-12-02637" ref-type="bibr">78</xref>,<xref rid="B79-biomedicines-12-02637" ref-type="bibr">79</xref>,<xref rid="B80-biomedicines-12-02637" ref-type="bibr">80</xref>]. Therefore, immune changes associated with ECT in schizophrenia may be perceived as an integral part of the therapeutic effect of this treatment. ECT-induced increase in BDNF, which is linked to neuroplasticity, has been considered to be a predictor of positive clinical outcomes [<xref rid="B80-biomedicines-12-02637" ref-type="bibr">80</xref>]. ECT generates transient immune system activation but ultimately leads to attenuation of both peripheral inflammation and neuroinflammation. Wang and Zhang, (2024), revealed that repeated ECT decreases the number of neutrophils and the neutrophils to leukocytes ratio in patients with schizophrenia; i.e., peripheral inflammation was significantly reduced following ECT [<xref rid="B81-biomedicines-12-02637" ref-type="bibr">81</xref>]. On the other hand, the ECT effect on anti-inflammatory cytokines has not been hitherto well studied [<xref rid="B82-biomedicines-12-02637" ref-type="bibr">82</xref>]. Rojas et al., 2022 [<xref rid="B78-biomedicines-12-02637" ref-type="bibr">78</xref>], proposed a hypothetical model of non-specific ECT influence on the immune system in psychiatric disorders in which reduction in the pro-inflammatory (IL-6, TNF-&#945;) and increase in anti-inflammatory (IL-4, TGF-&#946;1) cytokine levels is paralleled in the CNS immune systems&#8217; function, i.e., diminution of microglia and astrocyte activity [<xref rid="B78-biomedicines-12-02637" ref-type="bibr">78</xref>]. It has not been proven whether this model is adequate for schizophrenia.</p><p>With regard to TRS patients, data suggest that ECT may decrease the severity of schizophrenia symptoms, not only through changing the activity of the immune system, but also through the neurotropic system. It was found that increased levels of both BDNF and VEGF induced by ECT in TRS patients post-ECT vs. pre-ECT were positively correlated with improvement of clinical symptoms (significant reduction in the PANSS positive, negative and total scales) [<xref rid="B33-biomedicines-12-02637" ref-type="bibr">33</xref>,<xref rid="B35-biomedicines-12-02637" ref-type="bibr">35</xref>,<xref rid="B36-biomedicines-12-02637" ref-type="bibr">36</xref>,<xref rid="B40-biomedicines-12-02637" ref-type="bibr">40</xref>]. Moreover, increased BDNF levels may enhance dopamine synthesis, its turnover and the functioning of the dopaminergic system, which are disrupted in TRS patients [<xref rid="B35-biomedicines-12-02637" ref-type="bibr">35</xref>]. Also, both BDNF and VEGF have been proven to reversibly modulate hippocampal synaptic plasticity and to improve hippocampal activity related to learning and memory [<xref rid="B36-biomedicines-12-02637" ref-type="bibr">36</xref>]. Thus, these neurotrophins may indirectly be involved in the improvement of cognitive function in TRS patients after ECT. Furthermore, ECT increases blood&#8211;brain barrier permeability, which allows medications to enter the brain, accumulate in higher amounts and express their therapeutic effect (decrease symptoms of schizophrenia) [<xref rid="B83-biomedicines-12-02637" ref-type="bibr">83</xref>]. Another possible mechanism by which ECT may influence the symptoms of schizophrenia in TRS patients is connected with ECT-induced changes in gray matter volume [<xref rid="B84-biomedicines-12-02637" ref-type="bibr">84</xref>], and with microstructural changes in the limbic system [<xref rid="B85-biomedicines-12-02637" ref-type="bibr">85</xref>,<xref rid="B86-biomedicines-12-02637" ref-type="bibr">86</xref>]. Kawashima et al., 2023 [<xref rid="B84-biomedicines-12-02637" ref-type="bibr">84</xref>], found that a regional gray matter volume (GMV) increase in the left pregenual anterior cingulate cortex was significantly correlated with percentage changes on the BPRS. Also, microstructural changes in key limbic structures (the left hippocampus and the right amygdala), observed in the ECT group, but not in the medication-only group, and hypothetically reflected by MRI texture, are associated with a clinical response to ECT in psychosis [<xref rid="B85-biomedicines-12-02637" ref-type="bibr">85</xref>]. This confirmed the result of an earlier study conducted by Yang et al., 2020 [<xref rid="B86-biomedicines-12-02637" ref-type="bibr">86</xref>], in which a decrease in functional connectivity post-ECT compared to pre-treatment between the right amygdala and the left hippocampus correlated positively with a percentage reduction in the PANSS total score. These findings support the neuroplasticity hypothesis of ECT and highlight the hippocampus and amygdala as potential targets for neuromodulation in psychosis [<xref rid="B85-biomedicines-12-02637" ref-type="bibr">85</xref>].</p><p>To this end, we have found a statistically significant decrease in concentrations of pro-inflammatory cytokines IL-6 (<italic toggle="yes">p</italic> = 0.012), IL-12 (<italic toggle="yes">p</italic> = 0.049) after ECT in comparison to pre-ECT, and no significant difference in IL-5 and TGF-&#946;1 concentration after ECT was noticed. Kartalci et al., 2016 [<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>], showed that anti-inflammatory cytokines TGF-&#946;1 and IL-4 were increased after ECT and proposed that this could balance the inflammatory state in patients with schizophrenia. The mechanism and meaning of such an increase in IL-4 and TGF-&#946;1 serum concentrations are not clear. Although the increase in serum TGF-&#946;1 and IL-4 may be caused by electrical stimulation alone, this may also be a secondary phenomenon related to the effects of neurotransmitters or neuroendocrine mediators [<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>]. TGF-&#946;1 also inhibits production of pro-inflammatory cytokines produced by macrophages and Th-1 cells (IL-1&#946;, IL-6, IL-12, TNF-&#945;, IFN, IL-13) and Th-17 cells (IL-17), and stimulates the production of sIL-1RA, which exerts an anti-inflammatory effect. Therefore, it may be hypothesized that reductions in serum IL-6 and IL-12 that were observed after ECT, at least in part, could be the result of increased production of TGF-&#946;1, as this cytokine inhibits IL-6 and IL-12 synthesis. Also, IL-5 (produced by Th2 cells) and IL-10 (produced by Treg cells) may have immune-regulatory effects and with TGF-&#946;1 may exert an anti-inflammatory effect (CIRS). IL-10 enhances the release of IL-1RA from macrophages and suppresses Th-1, M1, dendritic and cytotoxic cells, as well as B and natural killer (NK) cells, whereas IL-5 is a growth factor for B cells and eosinophils. However, according to some authors, IL-5 plays a role in neuroinflammation by increasing the activation and proliferation of microglial cells and has an adverse effect on brain neuronal functioning and neuroprotective processes [<xref rid="B63-biomedicines-12-02637" ref-type="bibr">63</xref>,<xref rid="B87-biomedicines-12-02637" ref-type="bibr">87</xref>].</p><p>There is evidence that ECT-induced improvement in schizophrenia psychopathology has different neurobiological correlates than improvement in the result of solitary neuroleptic therapy. Jiang et al., 2019 [<xref rid="B88-biomedicines-12-02637" ref-type="bibr">88</xref>], observed bilateral hippocampal volume increase in a group of 21 schizophrenic patients treated with ECT, in both responders and non-responders, and this was not present in a similar group undergoing pharmacological therapy with antipsychotics. Moreover, increased functional connectivity between the hippocampus and brain networks associated with cognitive function was shown only in the ECT-responders [<xref rid="B88-biomedicines-12-02637" ref-type="bibr">88</xref>]. Assessment of insula volume in 21 schizophrenic patients treated with ECT and antipsychotics revealed an increase in posterior regions, which was associated with symptomatology reduction. Conversely, in the control group of patients treated with antipsychotics only, a reduction in volume in posterior insula areas was observed [<xref rid="B89-biomedicines-12-02637" ref-type="bibr">89</xref>]. Another study found increased functional connectivity between the thalamus and putamen in schizophrenic patients following 4-week ECT that was not present in patients treated with antipsychotics [<xref rid="B90-biomedicines-12-02637" ref-type="bibr">90</xref>]. Also, different patterns of function of cerebral&#8211;cerebellar loops in schizophrenic patients who clinically improved after antipsychotic treatment only, as compared to patients following ECT, was described [<xref rid="B91-biomedicines-12-02637" ref-type="bibr">91</xref>]. Two studies of default mode network (DMN) density in 21 schizophrenic patients after four weeks of combined ECT plus antipsychotic therapy found increased global functional connectivity within the DMN, which was associated with symptom improvement, and this effect was not seen in patients treated with neuroleptics [<xref rid="B92-biomedicines-12-02637" ref-type="bibr">92</xref>]. Gray matter volume in four studied brain regions following 4-week ECT in 21 schizophrenic patients was increased and this may indicate brain plasticity induction by ECT, which was not observed in patients on antipsychotic therapy. Positive symptom reduction was linked to gray matter increases in limbic areas (i.e., parahippocampal gyrus and hippocampus) [<xref rid="B93-biomedicines-12-02637" ref-type="bibr">93</xref>]. These results suggest a more complex and multimodal action of ECT in schizophrenia in comparison to antipsychotic treatment.</p></sec><sec sec-type="conclusions" id="sec5-biomedicines-12-02637"><title>5. Conclusions and Limitations</title><p>This study reveals a significant decrease in the PANSS positive symptoms, PANSS negative symptoms, PANSS general symptoms and PANSS total score in TRS patients, which reflects a substantial improvement in psychopathology following ECT. However, because no correlation between any of the measured cytokines (IL-6, IL-12, IL-5, IL-10, TGF-&#946;1) and positive, negative, general or total PANSS scores pre-ECT was found in the presented data, making any prediction about the therapeutic effect of the treatment via correlations with cytokine changes in TRS patients seems to be currently impossible and requires further research. Moreover, comparison of IL-6, IL-12 and IL-10 concentration before and after ECT revealed a significant reduction in the concentration of these cytokines, whereas IL-5 and TGF-&#946;1 were not changed in TRS patients. The presented data also indicate that the lack of IL-6 and IL-12 concentration differences in TRS patients prior to ECT as compared to the control group may suggest that IL-6 is a state marker, whereas IL-12 seems not to be a trait marker in TRS patients. However, there is sufficient clinical and neurobiological evidence to support the efficacy of ECT in TRS patients; nonetheless, data on the immune system involvement in therapeutic processes are still scarce and therefore it is impossible to detect a meticulous mechanism of action of this treatment.</p><p>There are some limitations to our study. Mainly, the study was heterogenous and featured a small sample of TRS patients. Factors such as differentiated diet, smoking habits, psychological stress and lifestyle may have affected cytokine profiles [<xref rid="B94-biomedicines-12-02637" ref-type="bibr">94</xref>,<xref rid="B95-biomedicines-12-02637" ref-type="bibr">95</xref>,<xref rid="B96-biomedicines-12-02637" ref-type="bibr">96</xref>,<xref rid="B97-biomedicines-12-02637" ref-type="bibr">97</xref>]. Secondly, all patients had been treated with different combinations of medications, including antipsychotics, mood stabilizers and antidepressants before drug-resistance developed, so immune balance (activation of both IRS and CIRS systems) was already affected by pharmacotherapy. Additionally, all patients were on psychopharmacological treatment during ECT, and although doses were decreased, this probably modified both the expression and magnitude of inflammatory markers released into blood. However, conducting ECT in TRS patients without psychotropic treatment may not be possible due to ethical issues. Moreover, the induction of anesthesia and administration of muscle relaxants prior to the administration of ECT may also change the concentration of cytokines, for example, by reducing IL-1&#946; and TNF-&#945; levels [<xref rid="B98-biomedicines-12-02637" ref-type="bibr">98</xref>]. Another issue is the blood collection time-point. Blood samples for our study were collected in the morning between 7.00 and 7.30 the day before beginning ECT and on the day after the last course of ECT. There is evidence of both acute and long-term effects of ECT on inflammatory parameters [<xref rid="B99-biomedicines-12-02637" ref-type="bibr">99</xref>]; therefore, our blood collection time-point may be not optimal to detect all cytokine changes associated with ECT. Optimization of the time-point for cytokines measurements requires complete time-course studies, which have not been conducted so far. Also, ELISA kits used to assay cytokine levels were manufactured by different companies, so the quality of antibodies used in ELISA kits, the kit manufacture, and the operator&#8217;s skills may have affected the measurements [<xref rid="B100-biomedicines-12-02637" ref-type="bibr">100</xref>]. Lastly, comorbidity, diet, alcohol consumption, sex and menstrual cycle should be controlled as they all affect the concentration of immunological markers. In sum, more comprehensive research including the issues mentioned above in larger groups of patients is recommended.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Peter Ko&#347;mider-Jones, a native speaker, for proofreading this manuscript.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, A.M.S.; methodology, A.M.S.; software, M.&#262;.-J. and A.M.S.; validation, I.R., P.G. and K.L.; formal Analysis, A.M.S., I.R., P.G. and M.&#262;.-J.; investigation, I.R. and P.G.; resources, A.M.S.; data curation, A.M.S., M.&#262;.-J. and W.D.; writing&#8212;original draft preparation, A.M.S. and I.R.; writing&#8212;review and editing, W.D., M.&#262;.-J. and A.M.S.; visualization, A.M.S.; supervision, W.D.; project administration, A.M.S.; funding acquisition, W.D. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Nicolaus Copernicus University in Toru&#324; Collegium Medicum in Bydgoszcz, Poland. Approval number KB 631/2018, obtained on 24 October 2018.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in the study are available on request from the corresponding author(s).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>absolute neutrophil count (ANC); beta2 microglobulin (B2M); blood&#8211;brain barrier (BBB); brain-derived neurotrophic factor- BDNF production; Brief Psychiatric Rating Scale (BPRS); C-reactive protein (CRP); cerebrospinal fluid (CSF); Compensatory Immune Response System (CIRS).; electroconvulsive therapy (ECT); hypothalamus&#8211;pituitary&#8211;adrenal (HPA); the hypothalamus&#8211;pituitary&#8211;thyroid (HPT); IL-6 receptor (IL-6R); IL-1R antagonist (IL-1RA); Inflammatory Response System (IRS); interferon &#947; (IFN-&#947;); macrophage inflammatory protein 1&#945; (MIP-1&#945;); malignant neuroleptic syndrome (NMS); myeloperoxidase (MPO); nuclear factor-kB (NF-kB); obsessive&#8211;compulsive disorder (OCD); Positive and Negative Syndrome Scale (PANSS); post-traumatic stress disorder (PTSD; Parkinson&#8217;s disease (PD); schizophrenia (SZ); transforming growth factor &#946; (TGF-&#946;); treatment resistant depression (TRD); treatment-resistant schizophrenia (TRS); tryptophan catabolites (TRYCATs); tumor necrosis factor-alpha [TNF-&#945;].</p></glossary><ref-list><title>References</title><ref id="B1-biomedicines-12-02637"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>C.</given-names></name></person-group><article-title>Investigation of peripheral inflammatory biomarkers in association with violence in schizophrenia</article-title><source>BMC Psychiatry</source><year>2024</year><volume>24</volume><elocation-id>542</elocation-id><pub-id pub-id-type="doi">10.1186/s12888-024-05966-y</pub-id><pub-id pub-id-type="pmid">39085826</pub-id><pub-id pub-id-type="pmcid">PMC11293062</pub-id></element-citation></ref><ref id="B2-biomedicines-12-02637"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name></person-group><article-title>The Role of Cytokines in Predicting the Efficacy of Acute Stage Treatment in Patients with Schizophrenia</article-title><source>Neuropsychiatr. Dis. Treat.</source><year>2020</year><volume>21</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.2147/NDT.S218483</pub-id><pub-id pub-id-type="pmid">32021213</pub-id><pub-id pub-id-type="pmcid">PMC6982444</pub-id></element-citation></ref><ref id="B3-biomedicines-12-02637"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Dujaili</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Mousa</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Al-Hakeim</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations with Interleukin-6, Symptom Domains, and Neurocognitive Impairments</article-title><source>Schizophr. Bull.</source><year>2021</year><volume>47</volume><fpage>530</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbaa136</pub-id><pub-id pub-id-type="pmid">32971537</pub-id><pub-id pub-id-type="pmcid">PMC7965081</pub-id></element-citation></ref><ref id="B4-biomedicines-12-02637"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roomruangwong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Noto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kanchanatawan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kubera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: The IRS-CIRS Theory of Schizophrenia</article-title><source>Mol. Neurobiol.</source><year>2020</year><volume>57</volume><fpage>778</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1007/s12035-019-01737-z</pub-id><pub-id pub-id-type="pmid">31473906</pub-id></element-citation></ref><ref id="B5-biomedicines-12-02637"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saetre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Emilsson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Axelsson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kreuger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lindholm</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jazin</surname><given-names>E.</given-names></name></person-group><article-title>Inflammation-related genes up-regulated in schizophrenia brains</article-title><source>BMC Psychiatry</source><year>2007</year><volume>7</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.1186/1471-244X-7-46</pub-id><pub-id pub-id-type="pmid">17822540</pub-id><pub-id pub-id-type="pmcid">PMC2080573</pub-id></element-citation></ref><ref id="B6-biomedicines-12-02637"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name></person-group><article-title>Toxoplasma gondii infection positively associated with schizophrenia: Evidences from UK Biobank cohort and case-controlled studies</article-title><source>J. Psychiatr. Res.</source><year>2024</year><volume>175</volume><fpage>243</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2024.05.025</pub-id><pub-id pub-id-type="pmid">38749298</pub-id></element-citation></ref><ref id="B7-biomedicines-12-02637"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cullen</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pollak</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Blackman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Kempton</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mondelli</surname><given-names>V.</given-names></name></person-group><article-title>Associations between Non-Neurological Autoimmune Disorders and Psychosis: A Meta-analysis</article-title><source>Biol. Psychiatry</source><year>2019</year><volume>85</volume><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2018.06.016</pub-id><pub-id pub-id-type="pmid">30122288</pub-id><pub-id pub-id-type="pmcid">PMC6269125</pub-id></element-citation></ref><ref id="B8-biomedicines-12-02637"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leboyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Godin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Terro</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boukouaci</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Andre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aouizerate</surname><given-names>B.</given-names></name><name name-style="western"><surname>Berna</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Capdevielle</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study</article-title><source>Schizophr. Bull. Open</source><year>2021</year><volume>2</volume><fpage>sgab012</fpage><pub-id pub-id-type="doi">10.1093/schizbullopen/sgab012</pub-id><pub-id pub-id-type="pmid">34901861</pub-id><pub-id pub-id-type="pmcid">PMC8650073</pub-id></element-citation></ref><ref id="B9-biomedicines-12-02637"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howes</surname><given-names>O.D.</given-names></name><name name-style="western"><surname>McCutcheon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Agid</surname><given-names>O.</given-names></name><name name-style="western"><surname>de Bartolomeis</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Beveren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Birnbaum</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Bloomfield</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bressan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Carpenter</surname><given-names>W.T.</given-names></name><etal/></person-group><article-title>Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology</article-title><source>Am. J. Psychiatry</source><year>2017</year><volume>174</volume><fpage>216</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2016.16050503</pub-id><pub-id pub-id-type="pmid">27919182</pub-id><pub-id pub-id-type="pmcid">PMC6231547</pub-id></element-citation></ref><ref id="B10-biomedicines-12-02637"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuipers</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yesufu-Udechuku</surname><given-names>A.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kendall</surname><given-names>T.</given-names></name></person-group><article-title>Management of psychosis and schizophrenia in adults: Summary of updated NICE guidance</article-title><source>BMJ</source><year>2014</year><volume>348</volume><fpage>g117</fpage><pub-id pub-id-type="doi">10.1136/bmj.g1173</pub-id><pub-id pub-id-type="pmid">24523363</pub-id></element-citation></ref><ref id="B11-biomedicines-12-02637"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Bressan</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Gadelha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brietzke</surname><given-names>E.</given-names></name></person-group><article-title>High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance</article-title><source>World J. Biol. Psychiatry</source><year>2015</year><volume>16</volume><fpage>422</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.3109/15622975.2015.1062552</pub-id><pub-id pub-id-type="pmid">26212792</pub-id></element-citation></ref><ref id="B12-biomedicines-12-02637"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fond</surname><given-names>G.</given-names></name><name name-style="western"><surname>Godin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Berna</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andrianarisoa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coulon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brunel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bulzacka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aouizerate</surname><given-names>B.</given-names></name><name name-style="western"><surname>Capdevielle</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort</article-title><source>Eur. Arch. Psychiatry Clin. Neurosci.</source><year>2019</year><volume>269</volume><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1007/s00406-018-0908-0</pub-id><pub-id pub-id-type="pmid">29808267</pub-id></element-citation></ref><ref id="B13-biomedicines-12-02637"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bosmans</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kenis</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Meltzer</surname><given-names>H.Y.</given-names></name></person-group><article-title>In vivo immunomodulatory effects of clozapine in schizophrenia</article-title><source>Schizophr. Res.</source><year>1997</year><volume>26</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(97)00057-1</pub-id><pub-id pub-id-type="pmid">9323354</pub-id></element-citation></ref><ref id="B14-biomedicines-12-02637"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noto</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>S.O.V.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Rossaneis</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Verri</surname><given-names>W.A.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Cordeiro</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Belangero</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Gadelha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bressan</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis</article-title><source>Eur. Neuropsychopharmacol.</source><year>2019</year><volume>29</volume><fpage>416</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2018.12.008</pub-id><pub-id pub-id-type="pmid">30594344</pub-id></element-citation></ref><ref id="B15-biomedicines-12-02637"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sirivichayakul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michelin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>de Oliveira Seme&#227;o</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Lima Pedr&#227;o</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Geffard</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Increased Levels of Plasma Tumor Necrosis Factor-&#945; Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity</article-title><source>Mol. Neurobiol.</source><year>2020</year><volume>57</volume><fpage>2333</fpage><lpage>2345</lpage><comment>Erratum in <italic toggle="yes">Mol. Neurobiol.</italic><bold>2022</bold>, <italic toggle="yes">59</italic>, 1350</comment><pub-id pub-id-type="doi">10.1007/s12035-020-01882-w</pub-id><pub-id pub-id-type="pmid">32040834</pub-id></element-citation></ref><ref id="B16-biomedicines-12-02637"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Eyre</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jacka</surname><given-names>F.N.</given-names></name><name name-style="western"><surname>Dodd</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dean</surname><given-names>O.</given-names></name><name name-style="western"><surname>McEwen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Debnath</surname><given-names>M.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amminger</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis</article-title><source>Neurosci. Biobehav. Rev.</source><year>2016</year><volume>65</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.03.017</pub-id><pub-id pub-id-type="pmid">27073049</pub-id><pub-id pub-id-type="pmcid">PMC4876729</pub-id></element-citation></ref><ref id="B17-biomedicines-12-02637"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moylan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name></person-group><article-title>Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2014</year><volume>48</volume><fpage>512</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1177/0004867414533012</pub-id><pub-id pub-id-type="pmid">24803587</pub-id></element-citation></ref><ref id="B18-biomedicines-12-02637"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liddelow</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Guttenplan</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Bohlen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Schirmer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>M&#252;nch</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>Neurotoxic reactive astrocytes are induced by activated microglia</article-title><source>Nature</source><year>2017</year><volume>541</volume><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/nature21029</pub-id><pub-id pub-id-type="pmid">28099414</pub-id><pub-id pub-id-type="pmcid">PMC5404890</pub-id></element-citation></ref><ref id="B19-biomedicines-12-02637"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kanba</surname><given-names>S.</given-names></name></person-group><article-title>Cytokines and schizophrenia: Microglia hypothesis of schizophrenia</article-title><source>Psychiatry Clin. Neurosci.</source><year>2009</year><volume>63</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1819.2009.01945.x</pub-id><pub-id pub-id-type="pmid">19579286</pub-id></element-citation></ref><ref id="B20-biomedicines-12-02637"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sirivichayakul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kanchanatwan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thika</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>A new schizophrenia model: Immune activation is associated with induction of the tryptophan catabolite pathway and increased eotaxin levels which together determine memory impairments and schizophrenia symptom dimensions</article-title><source>bioRxiv</source><year>2018</year><pub-id pub-id-type="doi">10.1101/393173</pub-id><pub-id pub-id-type="pmid">30451122</pub-id></element-citation></ref><ref id="B21-biomedicines-12-02637"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hakeim</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Almulla</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Al-Dujaili</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia</article-title><source>Curr. Top Med. Chem.</source><year>2020</year><volume>20</volume><fpage>747</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.2174/1568026620666200128143948</pub-id><pub-id pub-id-type="pmid">31994463</pub-id></element-citation></ref><ref id="B22-biomedicines-12-02637"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>A.F.</given-names></name></person-group><article-title>The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder</article-title><source>Mol. Neurobiol.</source><year>2018</year><volume>55</volume><fpage>8885</fpage><lpage>8903</lpage><pub-id pub-id-type="doi">10.1007/s12035-018-1016-x</pub-id><pub-id pub-id-type="pmid">29611101</pub-id></element-citation></ref><ref id="B23-biomedicines-12-02637"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arandjelovic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dragojlovic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Campana</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Gonias</surname><given-names>S.L.</given-names></name></person-group><article-title>A derivative of the plasma protease inhibitor alpha(2)-macroglobulin regulates the response to peripheral nerve injury</article-title><source>J. Neurochem.</source><year>2007</year><volume>103</volume><fpage>694</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.04800.x</pub-id><pub-id pub-id-type="pmid">17725582</pub-id></element-citation></ref><ref id="B24-biomedicines-12-02637"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanchanatawan</surname><given-names>B.</given-names></name></person-group><article-title>In (deficit) schizophrenia, a general cognitive decline partly mediates the effects of neuro-immune and neuro-oxidative toxicity on the symptomatome and quality of life</article-title><source>CNS Spectr.</source><year>2021</year><volume>12</volume><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1017/S1092852921000419</pub-id><pub-id pub-id-type="pmid">33843548</pub-id></element-citation></ref><ref id="B25-biomedicines-12-02637"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia</article-title><source>Eur. Neuropsychopharmacol.</source><year>2023</year><volume>72</volume><fpage>18</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2023.03.014</pub-id><pub-id pub-id-type="pmid">37058967</pub-id></element-citation></ref><ref id="B26-biomedicines-12-02637"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debnath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name></person-group><article-title>Th17 pathway-mediated immunopathogenesis of schizophrenia: Mechanisms and implications</article-title><source>Schizophr. Bull.</source><year>2014</year><volume>40</volume><fpage>1412</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbu049</pub-id><pub-id pub-id-type="pmid">24711545</pub-id><pub-id pub-id-type="pmcid">PMC4193719</pub-id></element-citation></ref><ref id="B27-biomedicines-12-02637"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bocchio Chiavetto</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bignotti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Battisa Tura</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pioli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kenis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bosmans</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Jongh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics</article-title><source>Eur. Neuropsychopharmacol.</source><year>2000</year><volume>10</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S0924-977X(99)00062-0</pub-id><pub-id pub-id-type="pmid">10706993</pub-id></element-citation></ref><ref id="B28-biomedicines-12-02637"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaster</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Daskalakis</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Blumberger</surname><given-names>D.M.</given-names></name></person-group><article-title>Clinical Effectiveness and Cognitive Impact of Electroconvulsive Therapy for Schizophrenia: A Large Retrospective Study</article-title><source>J. Clin. Psychiatry</source><year>2017</year><volume>78</volume><fpage>e383</fpage><lpage>e389</lpage><pub-id pub-id-type="doi">10.4088/JCP.16m10686</pub-id><pub-id pub-id-type="pmid">28297593</pub-id></element-citation></ref><ref id="B29-biomedicines-12-02637"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>C.Y.W.</given-names></name><name name-style="western"><surname>Abdin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peh</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Tor</surname><given-names>P.C.</given-names></name></person-group><article-title>Clinical effectiveness and speed of response of electroconvulsive therapy in treatment-resistant schizophrenia</article-title><source>Psychiatry Clin. Neurosci.</source><year>2019</year><volume>73</volume><fpage>416</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1111/pcn.12855</pub-id><pub-id pub-id-type="pmid">31026106</pub-id></element-citation></ref><ref id="B30-biomedicines-12-02637"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name><name name-style="western"><surname>Howes</surname><given-names>O.</given-names></name><name name-style="western"><surname>Siskind</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honer</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Falkai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schneider-Axmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>A.</given-names></name></person-group><article-title>Clozapine Combination and Augmentation Strategies in Patients with Schizophrenia-Recommendations from an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group</article-title><source>Schizophr. Bull.</source><year>2020</year><volume>46</volume><fpage>1459</fpage><lpage>1470</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbaa060</pub-id><pub-id pub-id-type="pmid">32421188</pub-id><pub-id pub-id-type="pmcid">PMC7846085</pub-id></element-citation></ref><ref id="B31-biomedicines-12-02637"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.-B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-B.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D.-B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Ungvari</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>C.U.</given-names></name></person-group><article-title>ECT augmentation of clozapine for clozapine resistant schizophrenia: A meta-analysis of randomized controlled trials</article-title><source>J. Psychiatr. Res.</source><year>2018</year><volume>105</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2018.08.002</pub-id><pub-id pub-id-type="pmid">30144667</pub-id></element-citation></ref><ref id="B32-biomedicines-12-02637"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenquist</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>A.</given-names></name></person-group><article-title>The Antipsychotic Effects of ECT: A Review of Possible Mechanisms</article-title><source>J. ECT</source><year>2014</year><volume>30</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1097/YCT.0000000000000131</pub-id><pub-id pub-id-type="pmid">24810776</pub-id></element-citation></ref><ref id="B33-biomedicines-12-02637"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sha</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia</article-title><source>Eur. Psychiatry</source><year>2016</year><volume>36</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2016.03.005</pub-id><pub-id pub-id-type="pmid">27311104</pub-id></element-citation></ref><ref id="B34-biomedicines-12-02637"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gohar</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>W.</given-names></name><name name-style="western"><surname>El-Makawi</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fakher</surname><given-names>W.</given-names></name><name name-style="western"><surname>Taher</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Abdel Samie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khalil</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>A.A.</given-names></name></person-group><article-title>Brain-Derived neurotrophic factor (BDNF) plasma level increases in patients with resistant schizophrenia treated with electroconvulsive therapy (ECT)</article-title><source>Int. J. Psychiatry Clin. Pract.</source><year>2022</year><volume>26</volume><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1080/13651501.2022.2035770</pub-id><pub-id pub-id-type="pmid">35192426</pub-id></element-citation></ref><ref id="B35-biomedicines-12-02637"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>V.</given-names></name><name name-style="western"><surname>Di Nicola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caltagirone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bria</surname><given-names>P.</given-names></name><name name-style="western"><surname>Angelucci</surname><given-names>F.</given-names></name></person-group><article-title>Brain-derived neurotrophic factor and electroconvulsive therapy in a schizophrenic patient with treatment-resistant paranoid-hallucinatory symptoms</article-title><source>J. ECT</source><year>2011</year><volume>27</volume><fpage>44</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1097/YCT.0b013e318205e1c0</pub-id><pub-id pub-id-type="pmid">21206369</pub-id></element-citation></ref><ref id="B36-biomedicines-12-02637"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sha</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Elevated serum vascular endothelial growth factor in treatment-resistant schizophrenia treated with electroconvulsive therapy: Positive association with therapeutic effects</article-title><source>World J. Biol. Psychiatry</source><year>2019</year><volume>20</volume><fpage>150</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1080/15622975.2018.1459048</pub-id><pub-id pub-id-type="pmid">29611450</pub-id></element-citation></ref><ref id="B37-biomedicines-12-02637"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akbas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Balaban</surname><given-names>O.D.</given-names></name></person-group><article-title>Changes in serum levels of brain-derived neurotrophic factor with electroconvulsive therapy and pharmacotherapy and its clinical correlates in male schizophrenia patients</article-title><source>Acta Neuropsychiatr.</source><year>2022</year><volume>34</volume><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1017/neu.2021.40</pub-id><pub-id pub-id-type="pmid">34924073</pub-id></element-citation></ref><ref id="B38-biomedicines-12-02637"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandes</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Massuda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Camargo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fries</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Gama</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Belmonte-de-Abreu</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Kapczinski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lobato</surname><given-names>M.I.</given-names></name></person-group><article-title>Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: Lack of association in a pilot study</article-title><source>Psychiatry Clin. Neurosci.</source><year>2010</year><volume>64</volume><fpage>663</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1819.2010.02153.x</pub-id><pub-id pub-id-type="pmid">21105955</pub-id></element-citation></ref><ref id="B39-biomedicines-12-02637"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Zubov</surname><given-names>D.S.</given-names></name></person-group><article-title>Electroconvulsive therapy in treatment of resistant schizophrenia: Biological markers of efficacy and safety</article-title><source>Zh. Nevrol. Psikhiatrii Im. S.S. Korsakova</source><year>2019</year><volume>119</volume><fpage>92</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.17116/jnevro201911903192</pub-id><pub-id pub-id-type="pmid">31089103</pub-id></element-citation></ref><ref id="B40-biomedicines-12-02637"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valiuliene</surname><given-names>G.</given-names></name><name name-style="western"><surname>Valiulis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dapsys</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vitkeviciene</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gerulskis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Navakauskiene</surname><given-names>R.</given-names></name><name name-style="western"><surname>Germanavicius</surname><given-names>A.</given-names></name></person-group><article-title>Brain stimulation effects on serum BDNF, VEGF, and TNF&#945; in treatment-resistant psychiatric disorders</article-title><source>Eur. J. Neurosci.</source><year>2021</year><volume>53</volume><fpage>3791</fpage><lpage>3802</lpage><pub-id pub-id-type="doi">10.1111/ejn.15232</pub-id><pub-id pub-id-type="pmid">33861484</pub-id></element-citation></ref><ref id="B41-biomedicines-12-02637"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartalci</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karabulut</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Erbay</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Acar</surname><given-names>C.</given-names></name></person-group><article-title>Effects of Electroconvulsive Therapy on Some Inflammatory Factors in Patients with Treatment-Resistant Schizophrenia</article-title><source>J. ECT</source><year>2016</year><volume>32</volume><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1097/YCT.0000000000000303</pub-id><pub-id pub-id-type="pmid">26886746</pub-id></element-citation></ref><ref id="B42-biomedicines-12-02637"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nucifora</surname><given-names>F.C.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Woznica</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Cascella</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sawa</surname><given-names>A.</given-names></name></person-group><article-title>Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives</article-title><source>Neurobiol. Dis.</source><year>2019</year><volume>131</volume><elocation-id>104257</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2018.08.016</pub-id><pub-id pub-id-type="pmid">30170114</pub-id><pub-id pub-id-type="pmcid">PMC6395548</pub-id></element-citation></ref><ref id="B43-biomedicines-12-02637"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Falkai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Siskind</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name></person-group><article-title>Characteristics and definitions of ultra-treatment-resistant schizophrenia&#8212;A systematic review and meta-analysis</article-title><source>Schizophr. Res.</source><year>2021</year><volume>228</volume><fpage>218</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2020.12.002</pub-id><pub-id pub-id-type="pmid">33454644</pub-id></element-citation></ref><ref id="B44-biomedicines-12-02637"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name><name name-style="western"><surname>Samara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heres</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.M.</given-names></name></person-group><article-title>Dose Equivalents for Antipsychotic Drugs: The DDD Method</article-title><source>Schizophr. Bull.</source><year>2016</year><volume>42</volume><fpage>S90</fpage><lpage>S94</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbv167</pub-id><pub-id pub-id-type="pmid">27460622</pub-id><pub-id pub-id-type="pmcid">PMC4960429</pub-id></element-citation></ref><ref id="B45-biomedicines-12-02637"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gronau</surname><given-names>Q.F.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wagenmakers</surname><given-names>E.J.</given-names></name></person-group><article-title>Informed Bayesian <italic toggle="yes">t</italic>-Tests</article-title><source>Am. Stat.</source><year>2019</year><volume>74</volume><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1080/00031305.2018.1562983</pub-id></element-citation></ref><ref id="B46-biomedicines-12-02637"><label>46.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Wagenmakers</surname><given-names>E.J.</given-names></name></person-group><source>Bayesian Modeling for Cognitive Science: A Practical Course</source><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2013</year></element-citation></ref><ref id="B47-biomedicines-12-02637"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Schoot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Depaoli</surname><given-names>S.</given-names></name><name name-style="western"><surname>King</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>B.</given-names></name><name name-style="western"><surname>M&#228;rtens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tadesse</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Vannucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gelman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Veen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Willemsen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Bayesian statistics and modelling</article-title><source>Nat. Rev. Methods Primers</source><year>2021</year><volume>1</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1038/s43586-020-00001-2</pub-id></element-citation></ref><ref id="B48-biomedicines-12-02637"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kenis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bignotti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tura</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>De Jong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bosmans</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pioli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Altamura</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scharp&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>The inflammatory response system in treatment-resistant schizophrenia: Increased serum interleukin-6</article-title><source>Schizophr. Res.</source><year>1998</year><volume>32</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/S0920-9964(98)00034-6</pub-id><pub-id pub-id-type="pmid">9690329</pub-id></element-citation></ref><ref id="B49-biomedicines-12-02637"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eftekharian</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Omrani</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Arsang-Jang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taheri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghafouri-Fard</surname><given-names>S.</given-names></name></person-group><article-title>Serum cytokine profile in schizophrenic patients</article-title><source>Hum. Antibodies</source><year>2019</year><volume>27</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.3233/HAB-180344</pub-id><pub-id pub-id-type="pmid">30103309</pub-id></element-citation></ref><ref id="B50-biomedicines-12-02637"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meltzer</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Bosmans</surname><given-names>E.</given-names></name></person-group><article-title>Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine</article-title><source>Acta Psychiatr. Scand.</source><year>1994</year><volume>89</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1994.tb01527.x</pub-id><pub-id pub-id-type="pmid">8067274</pub-id></element-citation></ref><ref id="B51-biomedicines-12-02637"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tourjman</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kouassi</surname><given-names>&#201;.</given-names></name><name name-style="western"><surname>Kou&#233;</surname><given-names>M.&#200;.</given-names></name><name name-style="western"><surname>Rocchetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fortin-Fournier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fusar-Poli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Potvin</surname><given-names>S.</given-names></name></person-group><article-title>Antipsychotics&#8217; effects on blood levels of cytokines in schizophrenia: A meta-analysis</article-title><source>Schizophr. Res.</source><year>2013</year><volume>151</volume><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2013.10.011</pub-id><pub-id pub-id-type="pmid">24200418</pub-id></element-citation></ref><ref id="B52-biomedicines-12-02637"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patlola</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Donohoe</surname><given-names>G.</given-names></name><name name-style="western"><surname>McKernan</surname><given-names>D.P.</given-names></name></person-group><article-title>Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis</article-title><source>J. Psychiatr. Res.</source><year>2023</year><volume>160</volume><fpage>126</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2023.01.042</pub-id><pub-id pub-id-type="pmid">36804109</pub-id></element-citation></ref><ref id="B53-biomedicines-12-02637"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sobi&#347;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rykaczewska-Czerwi&#324;ska</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#346;wi&#281;tochowska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gorczyca</surname><given-names>P.</given-names></name></person-group><article-title>Therapeutic effect of aripiprazole in chronic schizophrenia is accompanied by anti-inflammatory activity</article-title><source>Pharmacol. Rep.</source><year>2015</year><volume>67</volume><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2014.09.007</pub-id><pub-id pub-id-type="pmid">25712663</pub-id></element-citation></ref><ref id="B54-biomedicines-12-02637"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abedian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hamzeh Hosseini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akbarian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alizadeh-Navaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Taghipour</surname><given-names>M.</given-names></name></person-group><article-title>Serum TNF-&#945;, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine</article-title><source>Iran J. Immunol.</source><year>2014</year><volume>11</volume><fpage>200</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">25265997</pub-id></element-citation></ref><ref id="B55-biomedicines-12-02637"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frydecka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Krzystek-Korpacka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lubeiro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stramecki</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sta&#324;czykiewicz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Besz&#322;ej</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Piotrowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kotowicz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Szewczuk-Bogus&#322;awska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pawlak-Adamska</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Profiling inflammatory signatures of schizophrenia: A cross-sectional and meta-analysis study</article-title><source>Brain Behav. Immun.</source><year>2018</year><volume>71</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2018.05.002</pub-id><pub-id pub-id-type="pmid">29730395</pub-id></element-citation></ref><ref id="B56-biomedicines-12-02637"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bidwell</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>D.</given-names></name></person-group><article-title>Trait vs. State Markers for Schizophrenia: Identification and Characterization through Visual Processes</article-title><source>Curr. Psychiatry Rev.</source><year>2006</year><volume>2</volume><fpage>431</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.2174/157340006778699729</pub-id><pub-id pub-id-type="pmid">17487285</pub-id><pub-id pub-id-type="pmcid">PMC1866220</pub-id></element-citation></ref><ref id="B57-biomedicines-12-02637"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mondelli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ciufolini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Belvederi Murri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonaccorso</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Forti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Zunszain</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis</article-title><source>Schizophr. Bull.</source><year>2015</year><volume>41</volume><fpage>1162</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1093/schbul/sbv028</pub-id><pub-id pub-id-type="pmid">25829375</pub-id><pub-id pub-id-type="pmcid">PMC4535637</pub-id></element-citation></ref><ref id="B58-biomedicines-12-02637"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Momtazmanesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zare-Shahabadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group><article-title>Cytokine Alterations in Schizophrenia: An Updated Review</article-title><source>Front. Psychiatry</source><year>2019</year><volume>6</volume><elocation-id>892</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2019.00892</pub-id><pub-id pub-id-type="pmcid">PMC6915198</pub-id><pub-id pub-id-type="pmid">31908647</pub-id></element-citation></ref><ref id="B59-biomedicines-12-02637"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martins</surname><given-names>P.L.B.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>V.C.A.F.</given-names></name><name name-style="western"><surname>Arnaud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gama</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>J.P.</given-names></name></person-group><article-title>Immunoinflammatory and oxidative alterations in subjects with schizophrenia under clozapine: A meta-analysis</article-title><source>Eur. Neuropsychopharmacol.</source><year>2023</year><volume>4</volume><fpage>82</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2023.04.003</pub-id><pub-id pub-id-type="pmid">37148631</pub-id></element-citation></ref><ref id="B60-biomedicines-12-02637"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halstead</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siskind</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amft</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yakimov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shih-Jung Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Walder</surname><given-names>K.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>N.</given-names></name></person-group><article-title>Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: A systematic review and network meta-analysis</article-title><source>Lancet Psychiatr.</source><year>2023</year><volume>10</volume><fpage>260</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(23)00025-1</pub-id><pub-id pub-id-type="pmid">36863384</pub-id></element-citation></ref><ref id="B61-biomedicines-12-02637"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bragazzi</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Yogev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bar-Gad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Amital</surname><given-names>H.</given-names></name><name name-style="western"><surname>Amital</surname><given-names>D.</given-names></name></person-group><article-title>The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia</article-title><source>Psychiatry Res.</source><year>2018</year><volume>268</volume><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2018.07.041</pub-id><pub-id pub-id-type="pmid">30138859</pub-id></element-citation></ref><ref id="B62-biomedicines-12-02637"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trollor</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Sachdev</surname><given-names>P.S.</given-names></name></person-group><article-title>Electroconvulsive Treatment of Neuroleptic Malignant Syndrome: A Review and Report of Cases</article-title><source>Aust. N. Z. J. Psychiatry</source><year>1999</year><volume>33</volume><fpage>650</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1080/j.1440-1614.1999.00630.x</pub-id><pub-id pub-id-type="pmid">10544988</pub-id></element-citation></ref><ref id="B63-biomedicines-12-02637"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liva</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>de Vellis</surname><given-names>J.</given-names></name></person-group><article-title>IL-5 induces proliferation and activation of microglia via an unknown receptor</article-title><source>Neurochem. Res.</source><year>2001</year><volume>26</volume><fpage>629</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1023/A:1010983119125</pub-id><pub-id pub-id-type="pmid">11523538</pub-id></element-citation></ref><ref id="B64-biomedicines-12-02637"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kho</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Blansjaar</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babuskova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zwinderman</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Linszen</surname><given-names>D.H.</given-names></name></person-group><article-title>Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia&#8212;An open label study</article-title><source>Eur. Arch. Psychiatry Clin. Neurosci.</source><year>2004</year><volume>254</volume><fpage>372</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1007/s00406-004-0517-y</pub-id><pub-id pub-id-type="pmid">15538604</pub-id></element-citation></ref><ref id="B65-biomedicines-12-02637"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dimitrov</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yantis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Braida</surname><given-names>N.</given-names></name></person-group><article-title>Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: Potential role for IL-17 pathway</article-title><source>Schizophr. Res.</source><year>2013</year><volume>151</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2013.10.019</pub-id><pub-id pub-id-type="pmid">24210870</pub-id></element-citation></ref><ref id="B66-biomedicines-12-02637"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Plasma levelsof Th17 related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia</article-title><source>Psychiatry Res.</source><year>2016</year><volume>246</volume><fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2016.10.061</pub-id><pub-id pub-id-type="pmid">27829509</pub-id></element-citation></ref><ref id="B67-biomedicines-12-02637"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Catalase a interleukin-6 serum elevation in a prediction of treatment-resistance in male schizophrenia patients</article-title><source>Asian J. Psychiatry</source><year>2023</year><volume>79</volume><fpage>103400</fpage><pub-id pub-id-type="doi">10.1016/j.ajp.2022.103400</pub-id><pub-id pub-id-type="pmid">36521406</pub-id></element-citation></ref><ref id="B68-biomedicines-12-02637"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enache</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nikkheslat</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fathalla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deakin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Walters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lawrie</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Egerton</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Peripheral immune markers and antipsychotic non-response in psychosis</article-title><source>Schizophr. Res.</source><year>2021</year><volume>230</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2020.12.020</pub-id><pub-id pub-id-type="pmid">33667853</pub-id><pub-id pub-id-type="pmcid">PMC8224180</pub-id></element-citation></ref><ref id="B69-biomedicines-12-02637"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Relationship Between Curative Effect and Serum Inflammatory Factors Level in Male Patients with First-Episode Schizophrenia Treated with Olanzapine</article-title><source>Front. Psychiatry</source><year>2021</year><volume>12</volume><elocation-id>782289</elocation-id><pub-id pub-id-type="doi">10.3389/fpsyt.2021.782289</pub-id><pub-id pub-id-type="pmid">34955927</pub-id><pub-id pub-id-type="pmcid">PMC8695839</pub-id></element-citation></ref><ref id="B70-biomedicines-12-02637"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>D.</given-names></name></person-group><article-title>Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia</article-title><source>Shanghai Arch. Psychiatry</source><year>2017</year><volume>29</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">29276352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.11919/j.issn.1002-0829.217093</pub-id><pub-id pub-id-type="pmcid">PMC5738517</pub-id></element-citation></ref><ref id="B71-biomedicines-12-02637"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.C.</given-names></name></person-group><article-title>Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: Association with psychopathology and response to antipsychotics</article-title><source>Neuropsychopharmacology</source><year>2005</year><volume>30</volume><fpage>1532</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300756</pub-id><pub-id pub-id-type="pmid">15886721</pub-id></element-citation></ref><ref id="B72-biomedicines-12-02637"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrides</surname><given-names>G.</given-names></name><name name-style="western"><surname>Malur</surname><given-names>C.</given-names></name><name name-style="western"><surname>Braga</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bailine</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Schooler</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sanghani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>John</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study</article-title><source>Focus (Am. Psychiatr. Publ.)</source><year>2019</year><volume>17</volume><fpage>76</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1176/appi.focus.17106</pub-id><pub-id pub-id-type="pmid">32015718</pub-id><pub-id pub-id-type="pmcid">PMC6996075</pub-id></element-citation></ref><ref id="B73-biomedicines-12-02637"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>N.S.</given-names></name></person-group><article-title>Elective combined electroconvulsive and clozapine therapy</article-title><source>Int. Clin. Psychopharmacol.</source><year>1999</year><volume>14</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1097/00004850-199903000-00002</pub-id><pub-id pub-id-type="pmid">10220120</pub-id></element-citation></ref><ref id="B74-biomedicines-12-02637"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masoudzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khalilian</surname><given-names>A.R.</given-names></name></person-group><article-title>Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients</article-title><source>Pak. J. Biol. Sci.</source><year>2007</year><volume>10</volume><fpage>4287</fpage><lpage>4290</lpage><pub-id pub-id-type="doi">10.3923/pjbs.2007.4287.4290</pub-id><pub-id pub-id-type="pmid">19086588</pub-id></element-citation></ref><ref id="B75-biomedicines-12-02637"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>I.W.</given-names></name></person-group><article-title>Effectiveness of Electroconvulsive Therapy Augmentation on Clozapine-Resistant Schizophrenia</article-title><source>Psychiatry Investig.</source><year>2017</year><volume>14</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.4306/pi.2017.14.1.58</pub-id><pub-id pub-id-type="pmid">28096876</pub-id><pub-id pub-id-type="pmcid">PMC5240461</pub-id></element-citation></ref><ref id="B76-biomedicines-12-02637"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravani&#263;</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Pantovi&#263;</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Milovanovi&#263;</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Duki&#263;-Dejanovi&#263;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janji&#263;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ignjatovi&#263;</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Jovi&#263;</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Jurisi&#263;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jevtovi&#263;</surname><given-names>I.</given-names></name></person-group><article-title>Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia</article-title><source>Psychiatr. Danub.</source><year>2009</year><volume>21</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">19556946</pub-id></element-citation></ref><ref id="B77-biomedicines-12-02637"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Mekala</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Venigalla</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Etman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>M.</given-names></name></person-group><article-title>Combined use of electroconvulsive therapy and antipsychotics (both clozapine and non-clozapine) in treatment resistant schizophrenia: A comparative meta-analysis</article-title><source>Heliyon</source><year>2017</year><volume>3</volume><fpage>e00429</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2017.e00429</pub-id><pub-id pub-id-type="pmid">29264404</pub-id><pub-id pub-id-type="pmcid">PMC5727374</pub-id></element-citation></ref><ref id="B78-biomedicines-12-02637"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ariza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Ria&#241;o-Garz&#243;n</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ch&#225;vez-Castillo</surname><given-names>M.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Cudris-Torres</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bautista</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Medina-Ortiz</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rojas-Quintero</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>6918</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23136918</pub-id><pub-id pub-id-type="pmid">35805923</pub-id><pub-id pub-id-type="pmcid">PMC9266340</pub-id></element-citation></ref><ref id="B79-biomedicines-12-02637"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lho</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>J.S.</given-names></name></person-group><article-title>Systematic Review of the Neural Effect of Electroconvulsive Therapy in Patients with Schizophrenia: Hippocampus and Insula as the Key Regions of Modulation</article-title><source>Psychiatry Investig.</source><year>2021</year><volume>18</volume><fpage>486</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.30773/pi.2020.0438</pub-id><pub-id pub-id-type="pmcid">PMC8256139</pub-id><pub-id pub-id-type="pmid">34218638</pub-id></element-citation></ref><ref id="B80-biomedicines-12-02637"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arancibia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abarca</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pe&#241;a</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cavieres</surname><given-names>&#193;.</given-names></name></person-group><article-title>Posibles mecanismos de acci&#243;n de la terapia electroconvulsiva en esquizofrenia: Revisi&#243;n de la evidencia disponible en investigaci&#243;n con seres humanos [A review about the putative mechanisms of action of electroconvulsive therapy in schizophrenia in human research]</article-title><source>Rev. M&#233;d. Chile</source><year>2022</year><volume>150</volume><fpage>1493</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">37358175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4067/S0034-98872022001101493</pub-id></element-citation></ref><ref id="B81-biomedicines-12-02637"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>The role of immune inflammation in electroconvulsive therapy for schizophrenia: Treatment mechanism, and relationship with clinical efficacy: Immune-inflammation in ECT for schizophrenia</article-title><source>Psychiatry Res.</source><year>2024</year><volume>332</volume><fpage>115708</fpage><pub-id pub-id-type="doi">10.1016/j.psychres.2023.115708</pub-id><pub-id pub-id-type="pmid">38171169</pub-id></element-citation></ref><ref id="B82-biomedicines-12-02637"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Systemic inflammatory biomarkers in Schizophrenia are changed by ECT administration and related to the treatment efficacy</article-title><source>BMC Psychiatry</source><year>2024</year><volume>24</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1186/s12888-023-05469-2</pub-id><pub-id pub-id-type="pmid">38233774</pub-id><pub-id pub-id-type="pmcid">PMC10792810</pub-id></element-citation></ref><ref id="B83-biomedicines-12-02637"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davarinejad</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hendesi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shahi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khazaie</surname><given-names>H.</given-names></name></person-group><article-title>A Pilot Study on Daily Intensive ECT over 8 Days Improved Positive and Negative Symptoms and General Psychopathology of Patients with Treatment-Resistant Schizophrenia up to 4 Weeks After Treatment</article-title><source>Neuropsychobiology</source><year>2019</year><volume>77</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1159/000494698</pub-id><pub-id pub-id-type="pmid">30463074</pub-id></element-citation></ref><ref id="B84-biomedicines-12-02637"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawashima</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hazama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fushimi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>J.</given-names></name><name name-style="western"><surname>Murai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suwa</surname><given-names>T.</given-names></name></person-group><article-title>Commonalities and differences in ECT-induced gray matter volume change between depression and schizophrenia</article-title><source>Neuroimage Clin.</source><year>2023</year><volume>38</volume><fpage>103429</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2023.103429</pub-id><pub-id pub-id-type="pmid">37150022</pub-id><pub-id pub-id-type="pmcid">PMC10193002</pub-id></element-citation></ref><ref id="B85-biomedicines-12-02637"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>J.S.</given-names></name></person-group><article-title>MRI textural plasticity in limbic gray matter associated with clinical response to electroconvulsive therapy for psychosis</article-title><source>Mol. Psychiatry</source><year>2024</year><volume>26</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/s41380-024-02755-7</pub-id><pub-id pub-id-type="pmcid">PMC11919751</pub-id><pub-id pub-id-type="pmid">39327507</pub-id></element-citation></ref><ref id="B86-biomedicines-12-02637"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>W.</given-names></name></person-group><article-title>Predicting responses to electro convulsive therapy in schizophrenia patients undergoing antipsychotic treat ment: Baseline functional connectivity among regions with strong electric field distributions</article-title><source>Psychiatry Res. Neuroimaging</source><year>2020</year><volume>299</volume><fpage>111059</fpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2020.111059</pub-id><pub-id pub-id-type="pmid">32135406</pub-id></element-citation></ref><ref id="B87-biomedicines-12-02637"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanchanatawan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>M.</given-names></name></person-group><article-title>The effects of the tryptophan catabolite pathway on negative symptoms and deficit schizophrenia and partly mediated by executive impairments: Result of partial least squares path modeling</article-title><source>CNS Neurol. Disord. Drug Targets</source><year>2018</year><volume>17</volume><fpage>473</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.2174/1871527317666180702160921</pub-id><pub-id pub-id-type="pmid">29968545</pub-id></element-citation></ref><ref id="B88-biomedicines-12-02637"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name></person-group><article-title>Common increased hippocampal volume but specific changes in functional connectivity in schizophrenia patients in remission and non-remission following electroconvulsive therapy: A preliminary study</article-title><source>Neuroimage Clin.</source><year>2019</year><volume>24</volume><fpage>102081</fpage><pub-id pub-id-type="doi">10.1016/j.nicl.2019.102081</pub-id><pub-id pub-id-type="pmid">31734526</pub-id><pub-id pub-id-type="pmcid">PMC6861644</pub-id></element-citation></ref><ref id="B89-biomedicines-12-02637"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Insular changes induced by electroconvulsive therapy response to symptom improvements in schizophrenia</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2019</year><volume>89</volume><fpage>254</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2018.09.009</pub-id><pub-id pub-id-type="pmid">30248379</pub-id></element-citation></ref><ref id="B90-biomedicines-12-02637"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Altered functional connectivity of the thalamus induced by modified electroconvulsive therapy for schizophrenia</article-title><source>Schizophr. Res.</source><year>2020</year><volume>218</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2019.12.044</pub-id><pub-id pub-id-type="pmid">31956007</pub-id></element-citation></ref><ref id="B91-biomedicines-12-02637"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Functional reconfiguration of cerebellum-cerebral neural loop in schizophrenia following electroconvulsive therapy</article-title><source>Psychiatry Res. Neuroimaging</source><year>2022</year><volume>320</volume><fpage>111441</fpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2022.111441</pub-id><pub-id pub-id-type="pmid">35085957</pub-id></element-citation></ref><ref id="B92-biomedicines-12-02637"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Increased resting-state global functional connectivity density of default mode network in schizophrenia subjects treated with electroconvulsive therapy</article-title><source>Schizophr. Res.</source><year>2018</year><volume>197</volume><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2017.10.044</pub-id><pub-id pub-id-type="pmid">29117910</pub-id></element-citation></ref><ref id="B93-biomedicines-12-02637"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>ECT-induced brain plasticity correlates with positive symptom improvement in schizophrenia by voxel-based morphometry analysis of grey matter</article-title><source>Brain Stimul.</source><year>2019</year><volume>12</volume><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2018.11.006</pub-id><pub-id pub-id-type="pmid">30473477</pub-id></element-citation></ref><ref id="B94-biomedicines-12-02637"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>F.M.M.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Cecchini</surname><given-names>R.</given-names></name><name name-style="western"><surname>e Silva</surname><given-names>R.C.R.</given-names></name><name name-style="western"><surname>Macchione</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Toledo-Arruda</surname><given-names>A.C.</given-names></name><etal/></person-group><article-title>Nasal and systemic inflammatory profile after short term smoking cessation</article-title><source>Respir. Med.</source><year>2014</year><volume>108</volume><fpage>999</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2014.04.020</pub-id><pub-id pub-id-type="pmid">24863424</pub-id></element-citation></ref><ref id="B95-biomedicines-12-02637"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aziz</surname><given-names>N.</given-names></name></person-group><article-title>Measurement of circulating cytokines and immune-activation markers by multiplex technology in the clinical setting: What are we really measuring?</article-title><source>Immunopathol. Dis. Therap.</source><year>2015</year><volume>6</volume><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1615/ForumImmunDisTher.2015014162</pub-id><pub-id pub-id-type="pmcid">PMC5345938</pub-id><pub-id pub-id-type="pmid">28286693</pub-id></element-citation></ref><ref id="B96-biomedicines-12-02637"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>West</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Cripps</surname><given-names>A.W.</given-names></name></person-group><article-title>Obesity, inflammation, and the gut microbiota</article-title><source>Lancet Diabetes Endocrinol.</source><year>2015</year><volume>3</volume><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(14)70134-2</pub-id><pub-id pub-id-type="pmid">25066177</pub-id></element-citation></ref><ref id="B97-biomedicines-12-02637"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marsland</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lockwood</surname><given-names>K.</given-names></name><name name-style="western"><surname>John-Henderson</surname><given-names>N.A.</given-names></name></person-group><article-title>The effects of acute psychological stress on circulating and stimulated inflammatory markers: A systematic review and meta-analysis</article-title><source>Brain Behav. Immun.</source><year>2017</year><volume>64</volume><fpage>208</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2017.01.011</pub-id><pub-id pub-id-type="pmid">28089638</pub-id><pub-id pub-id-type="pmcid">PMC5553449</pub-id></element-citation></ref><ref id="B98-biomedicines-12-02637"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stelzhammer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rothermundt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guest</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sondermann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kluge</surname><given-names>W.</given-names></name><name name-style="western"><surname>Martins-de-Souza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rahmoune</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bahn</surname><given-names>S.</given-names></name></person-group><article-title>Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy</article-title><source>Proteom. Clin. Appl.</source><year>2011</year><volume>5</volume><fpage>644</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1002/prca.201100040</pub-id><pub-id pub-id-type="pmid">22006837</pub-id></element-citation></ref><ref id="B99-biomedicines-12-02637"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>D.M.</given-names></name></person-group><article-title>Peripheral blood inflammatory markers in depression: Response to electroconvulsive therapy and relationship with cognitive performance</article-title><source>Psychiatry Res.</source><year>2022</year><volume>315</volume><fpage>114725</fpage><pub-id pub-id-type="doi">10.1016/j.psychres.2022.114725</pub-id><pub-id pub-id-type="pmid">35870295</pub-id></element-citation></ref><ref id="B100-biomedicines-12-02637"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Fragala</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mcelhaney</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kuchel</surname><given-names>G.A.</given-names></name></person-group><article-title>Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research</article-title><source>Curr. Opin. Clin. Nutr. Metab. Care</source><year>2010</year><volume>13</volume><fpage>541</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1097/MCO.0b013e32833cf3bc</pub-id><pub-id pub-id-type="pmid">20657280</pub-id><pub-id pub-id-type="pmcid">PMC2955626</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="biomedicines-12-02637-f001" orientation="portrait"><label>Figure 1</label><caption><p>Associations between TGF-&#946;1 and IL-6 before (r = &#8722;0.143) and following ECT (r = &#8722;0.144) in eight treatment-resistant schizophrenic patients. Numbers are IDs of eight patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="biomedicines-12-02637-g001.jpg"/></fig><fig position="float" id="biomedicines-12-02637-f002" orientation="portrait"><label>Figure 2</label><caption><p>Relationship between IL-6 and TGF-&#946;1 in thirteen control subjects (r = 0.78; <italic toggle="yes">p</italic> = 0.002) Numbers are IDs of thirteen control subjects.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="biomedicines-12-02637-g002.jpg"/></fig><fig position="float" id="biomedicines-12-02637-f003" orientation="portrait"><label>Figure 3</label><caption><p>Association between TGF-&#946;1 and IL-6 cytokine changes from pre-ECT to post-ECT in eight treatment-resistant schizophrenic patients (Spearman r = 0.833; <italic toggle="yes">p</italic> = 0.01; R<sup>2</sup> = 0.789). Numbers are IDs of eight patients.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="biomedicines-12-02637-g003.jpg"/></fig><table-wrap position="float" id="biomedicines-12-02637-t001" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t001_Table 1</object-id><label>Table 1</label><caption><p>Patients and treatment characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sex</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Type of Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Length of Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ECT History</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Suicidal Attempts History</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SUD #</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clozapine Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chlorpromazine Equivalent of Combined AP</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Somatic Comorbidity</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Positive<break/>Pre/Post-ECT <break/>(% Change)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Negative Pre/Post-ECT <break/>(% Change)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS General Pre/Post-ECT <break/>(% Change)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS <break/>Total Pre/Post-ECT <break/>(% Change)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">700 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1870 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17/13<break/>(23.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/19<break/>(9.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45/28<break/>(28.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">83/60<break/>(27.7%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1150 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">diabetes, hyperthyroidism</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27/18<break/>(33.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33/16<break/>(51.5%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72/54<break/>(25%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">132/88<break/>(33.3%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">525 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25/14<break/>(44%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33/28<break/>(15.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58/43<break/>(25.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">116/85<break/>(26.7%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">675 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/17<break/>(19%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/16<break/>(33.3%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58/43<break/>(25.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">103/76<break/>(27%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes <sup>$</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">635 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11/9<break/>(18.2%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27/17<break/>(37%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52/36<break/>(30.8%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90/59<break/>(34.4%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes <sup>$</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">750 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1875 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">diabetes, hypertension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24/8<break/>(66.7%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28/23<break/>(17.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62/43<break/>(30.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">114/74<break/>(35.1%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">325 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hypertension</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21/12<break/>(42.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33/21<break/>(36.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65/41<break/>(36.9%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119/74<break/>(37.8%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">675 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1810 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25/13<break/>(48%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33/19<break/>(42.4%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">63/28<break/>(55.6%)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121/60<break/>(50.4%)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS <break/>mean % change</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.1%</td></tr></tbody></table><table-wrap-foot><fn><p>M&#8212;Male; F&#8212;female; P&#8212;schizophrenia paranoid type; R&#8212;schizophrenia residual type; SUD #&#8212;past substance use disorder; <sup>$</sup>&#8212;Nicotinism only.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biomedicines-12-02637-t002" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t002_Table 2</object-id><label>Table 2</label><caption><p>PANSS scores pre- and post-ECT in treatment-resistant schizophrenic patients (<italic toggle="yes">n</italic> = 8).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-ECT<break/>Mean (&#177;SD)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Post-ECT<break/>Mean (&#177;SD)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Bayesian t-Test for Dependent Variables</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS positive symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21.4 (&#177;5.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (&#177;3.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS negative symptoms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (&#177;4.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19.9 (&#177;4.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS <break/>general</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59.4 (&#177;8.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.5 (&#177;8.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS <break/>total score</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109.8 (&#177;16.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72 (&#177;11.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> &lt; 0.001</td></tr></tbody></table><table-wrap-foot><fn><p>SD&#8212;standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biomedicines-12-02637-t003" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t003_Table 3</object-id><label>Table 3</label><caption><p>Bayesian <italic toggle="yes">t</italic>-test for concentrations of cytokines pre- and post-ECT in schizophrenic patients (<italic toggle="yes">n</italic> = 8) and in control subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cytokine</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-ECT<break/>Mean SD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Post-ECT<break/>Mean SD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Controls<break/>Mean SD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-ECT vs. Controls</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Post-ECT vs. Controls</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pre-ECT vs. Post-ECT</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">458.4<break/>238.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">167.4<break/>160.77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">148.5<break/>78.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.757</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.011 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108.9<break/>45.82</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74<break/>15.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14.8<break/>5.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.234</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.2<break/>1.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.5<break/>10.83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.6<break/>2.81</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.153</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.822</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.202</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101.1<break/>38.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.7<break/>6.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">473.3<break/>118.09</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001 **</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.194</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001 *</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">465.3<break/>94.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">558.8<break/>123.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">291<break/>237.78</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.124</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.177</td></tr></tbody></table><table-wrap-foot><fn><p>Bayesian T&#8212;Student test, <italic toggle="yes">p</italic> value; * or **&#8212;significance.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biomedicines-12-02637-t004" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t004_Table 4</object-id><label>Table 4</label><caption><p>The Spearman correlation between cytokine concentrations and the PANSS score. Lower triangle&#8212;pre-ECT, and upper triangle (with light gray background)&#8212;post-ECT. Dark gray&#8212;corresponding variables correlated for measures before and following ECT.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Post-ECT<break/>Pre-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">IL-6</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">IL-12</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">IL-5</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">IL-10</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">TGF-&#946;1</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">PANSS Positive Symptoms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">PANSS Negative Symptoms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">PANSS General</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">PANSS Total<break/>Score</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IL-6</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.44</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.30</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.09</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IL-12</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.07</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.50</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.32</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.48</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IL-5</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.36</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.22</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.05</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>rIL-10</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.05</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.16</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TGF-&#946;1</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">&#8722;0.26</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
<bold>&#8722;0.79 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.59</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.49</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.53</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PANSS positive symptoms</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">
<bold>0.71 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.49</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.43</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">0.69</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PANSS negative symptoms</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.75 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">
<bold>0.63 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.11</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">&#8722;0.02</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PANSS general</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.72 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.80 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">
<bold>0.61 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#D9D9D9" rowspan="1" colspan="1">
<bold>0.88 **</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PANSS total score</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.86 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.91 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.93 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#A6A6A6" rowspan="1" colspan="1">
<bold>0.85 **</bold>
</td></tr></tbody></table><table-wrap-foot><fn><p>*: Correlation is significant at the 0.05 level (2-tailed); **: Correlation is significant at the 0.01 level (2-tailed).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biomedicines-12-02637-t005" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t005_Table 5</object-id><label>Table 5</label><caption><p>The Spearman correlations of cytokine concentrations in the control group (<italic toggle="yes">n</italic> = 13).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-6</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-12</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-5</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-10</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.78 **</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p>**: Correlation significant at the 0.01 level (2-tailed).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biomedicines-12-02637-t006" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t006_Table 6</object-id><label>Table 6</label><caption><p>The Spearman correlations between cytokine concentrations and differences in PANSS scores before and after ECT in schizophrenic patients (<italic toggle="yes">n</italic> = 8).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-6 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-12 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-5 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-10 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Positive Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Negative Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS General Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Total Pre/Post-ECT</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-6<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.40</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">IL-6<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.23</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.06</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.11</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.31</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.93 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">IL-12<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.07</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.43</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.28</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">
<bold>0.87 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">
<bold>0.74 *</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-5<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">IL-5<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.26</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">
<bold>&#8722;0.98 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.52</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.55</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.59</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-10<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.64</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.95 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">IL-10<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.33</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.10</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">TGF-&#946;1<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">
<bold>&#8722;0.76 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.19</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">
<bold>&#8722;0.93 **</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.40</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS positive<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.71 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.44</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.55</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">PANSS positive<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.49</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.11</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.04</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.66</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.15</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.28</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.37</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS negative<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.84 **</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">PANSS negative<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.16</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.22</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.08</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.51</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.62</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.47</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS general<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.04</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.78 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.85 **</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">PANSS general<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.36</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.28</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.65</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.21</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.17</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.32</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.02</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS total score<break/>pre-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.78 *</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.85 **</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">PANSS total score<break/>post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.41</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.00</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.12</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.29</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.16</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">&#8722;0.27</td><td align="center" valign="middle" style="border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">0.06</td></tr></tbody></table><table-wrap-foot><fn><p>*: Correlation is significant at the 0.05 level (2-tailed); **: Correlation is significant at the 0.01 level (2-tailed).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biomedicines-12-02637-t007" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t007_Table 7</object-id><label>Table 7</label><caption><p>The Spearman correlations between differences in both cytokine concentrations and the PANSS scores in treatment-resistant schizophrenic patients (<italic toggle="yes">n</italic> = 8).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-6 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-12 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-5 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IL-10 Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1<break/>Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Positive<break/>Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Negative<break/>Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS General<break/>Pre/Post-ECT</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PANSS Total<break/>Pre/Post-ECT</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-6 pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12 pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.26</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-5 pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.51</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.36</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.49</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-10 pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.24</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.07</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1 pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.08</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS positive<break/>pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.53</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.59</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS negative<break/>pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.77 *</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS general pre/post-ECT </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.81 *</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PANSS total score pre/post-ECT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p>*: Correlation is significant at the 0.05 level (2-tailed).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="biomedicines-12-02637-t008" orientation="portrait"><object-id pub-id-type="pii">biomedicines-12-02637-t008_Table 8</object-id><label>Table 8</label><caption><p>Changes in cytokine, interleukin and neurotrophin concentrations post-ECT vs. pre-ECT in TRS patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Study</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Number of Participants</th><th colspan="10" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Changes in Inflammatory Factors Pre/Post-ECT in TRS Patients</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRS</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BDNF</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEGF</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNF-&#945;</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-4</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NF-kB</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TGF-&#946;1</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-6</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-12</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-5</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IL-10</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fernandes et al., 2010 [<xref rid="B38-biomedicines-12-02637" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Martinotti et al., 2011<break/>[<xref rid="B35-biomedicines-12-02637" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8593;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Li et al., 2016<break/>[<xref rid="B33-biomedicines-12-02637" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8593;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kartalci et al., 2016<break/>[<xref rid="B41-biomedicines-12-02637" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8593;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8593;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Xiao et al., 2018 <break/>[<xref rid="B36-biomedicines-12-02637" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8593;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ivanov et al., 2019<break/>[<xref rid="B39-biomedicines-12-02637" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Akbas et al., 2021<break/>[<xref rid="B37-biomedicines-12-02637" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Valiuliene et al., 2021<break/>[<xref rid="B40-biomedicines-12-02637" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shahin et al., 2022<break/>[<xref rid="B34-biomedicines-12-02637" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8593;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>This study</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>8</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>13</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8596;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8595;</td></tr></tbody></table><table-wrap-foot><fn><p>BDNF&#8212;brain-derived neurotrophic factor; C&#8212;control group; ECT&#8212;electroconvulsive therapy; Nf-kB&#8212;nuclear factor-kB; N/A&#8212;not available; TGF-&#946;1 transforming growth factor &#946;1; TNF-&#945;&#8212;tumor necrosis factor &#945;; TRS&#8212;treatment resistant schizophrenia; &#8596; no change; &#8595; decreased; &#8593; increased.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>